

Prevention of Perinatal Group B Streptococcal Disease

Revised Guidelines from CDC

Prepared by
Stephanie Schrag, D. Phil.
Rachel Gorwitz, M.D.
Kristi Fultz-Butts, M.P.H.
Anne Schuchat, M.D.

*Division of Bacterial and Mycotic Diseases
National Center for Infectious Diseases*

Summary

Group B streptococcus (GBS) remains a leading cause of serious neonatal infection despite great progress in perinatal GBS disease prevention in the 1990s. In 1996, CDC, in collaboration with other agencies, published guidelines for the prevention of perinatal group B streptococcal disease (CDC. Prevention of perinatal group B streptococcal disease: a public health perspective. MMWR 1996;45[RR-7]:1–24). Data collected after the issuance of the 1996 guidelines prompted reevaluation of prevention strategies at a meeting of clinical and public health representatives in November 2001. This report replaces CDC's 1996 guidelines. The recommendations are based on available evidence and expert opinion where sufficient evidence was lacking. Although many of the recommendations in the 2002 guidelines are the same as those in 1996, they include some key changes:

- *Recommendation of universal prenatal screening for vaginal and rectal GBS colonization of all pregnant women at 35–37 weeks' gestation, based on recent documentation in a large retrospective cohort study of a strong protective effect of this culture-based screening strategy relative to the risk-based strategy*
- *Updated prophylaxis regimens for women with penicillin allergy*
- *Detailed instruction on prenatal specimen collection and expanded methods of GBS culture processing, including instructions on antimicrobial susceptibility testing*
- *Recommendation against routine intrapartum antibiotic prophylaxis for GBS-colonized women undergoing planned cesarean deliveries who have not begun labor or had rupture of membranes*
- *A suggested algorithm for management of patients with threatened preterm delivery*
- *An updated algorithm for management of newborns exposed to intrapartum antibiotic prophylaxis*

Although universal screening for GBS colonization is anticipated to result in further reductions in the burden of GBS disease, the need to monitor for potential adverse consequences of intrapartum antibiotic use, such as emergence of bacterial antimicrobial resistance or increased incidence or severity of non-GBS neonatal pathogens, continues, and intrapartum antibiotics are still viewed as an interim strategy until GBS vaccines achieve licensure.

Introduction

Group B streptococcus (GBS) emerged as the leading infectious cause of neonatal morbidity and mortality in the United States in the 1970s (1–4). Initial case series reported case-fatality ratios as high as 50%. In the early 1980s, clinical trials demonstrated that administering antibiotics during labor to women at risk of transmitting GBS to their newborns could prevent invasive disease in the first week of life (i.e., early-onset disease) (5). As a result of the collaborative efforts of clinicians, researchers, professional organizations, parent advocacy groups, and the public health community in the 1990s, recommendations for intrapartum prophylaxis to prevent

perinatal GBS disease were issued in 1996 by the American College of Obstetricians and Gynecologists (ACOG) (6) and CDC (7), and in 1997 by the American Academy of Pediatrics (8).

Those guidelines recommended the use of one of two prevention methods, a risk-based approach or a culture-based screening approach. Providers using the risk-based method identify candidates for intrapartum chemoprophylaxis according to the presence of any of the following intrapartum risk factors associated with early-onset disease: delivering at <37 weeks' gestation, having an intrapartum temperature $\geq 100.4^{\circ}\text{F}$ ($\geq 38.0^{\circ}\text{C}$), or rupture of membranes for ≥ 18 hours. The screening-based method recommends screening of all pregnant women for vaginal and rectal GBS colonization between 35 and 37 weeks' gestation. Colonized women are then offered intrapartum antibiotics at the time of labor. Under both strategies, women with GBS bacteriuria during their current

The material in this report was prepared by the National Center for Infectious Diseases, James M. Hughes, M.D., Director; Division of Bacterial and Mycotic Diseases, Mitchell L. Cohen, M.D., Director.

pregnancy, or who previously gave birth to an infant with early-onset GBS disease are candidates for intrapartum antibiotic prophylaxis.

Before active prevention was initiated, an estimated 7,500 cases of neonatal GBS disease occurred annually (9). Despite striking declines in disease incidence coinciding with increased prevention activities in the 1990s, GBS disease remains a leading infectious cause of morbidity and mortality among newborns in the United States (10,11). Moreover, since the release of the 1996 guidelines, new data are available to evaluate the effectiveness of the screening approach relative to the risk-based approach and to resolve some of the clinical challenges of implementing prevention.

In light of these new data, in November 2001, CDC consulted with multiple partners to revise the 1996 guidelines for the prevention of perinatal group B streptococcal disease, using an evidence-based approach where possible and scientific opinion when sufficient data were lacking (Table 1). These updated guidelines replace CDC's 1996 guidelines. They are intended for the following groups: providers of prenatal, obstetric, and pediatric care; supporting microbiology laboratories, hospital administrators and managed care organizations; childbirth educators; public health authorities; and expectant parents and their advocates.

Differences and similarities between current and previous guidelines

Following are major differences in the new guidelines:

- Recommendation of universal prenatal culture-based screening for vaginal and rectal GBS colonization of all pregnant women at 35–37 weeks' gestation
- Updated prophylaxis regimens for women with penicillin allergy

- Detailed instruction on prenatal specimen collection and expanded methods of GBS culture processing, including instructions on susceptibility testing
- Recommendation against routine intrapartum antibiotic prophylaxis for GBS-colonized women undergoing planned cesarean deliveries who have not begun labor or had rupture of membranes
- A suggested algorithm for management of patients with threatened preterm delivery
- An updated algorithm for management of newborns exposed to intrapartum antibiotic prophylaxis

Although important changes have been instituted, many recommendations remain the same:

- Penicillin remains the first-line agent for intrapartum antibiotic prophylaxis, with ampicillin an acceptable alternative.
- Women whose culture results are unknown at the time of delivery should be managed according to the risk-based approach; the obstetric risk factors remain unchanged (i.e., delivery at <37 weeks' gestation, duration of membrane rupture ≥ 18 hours, or temperature $\geq 100.4^{\circ}\text{F}$ [$\geq 38.0^{\circ}\text{C}$]).
- Women with negative vaginal and rectal GBS screening cultures within 5 weeks of delivery do not require intrapartum antimicrobial prophylaxis for GBS even if obstetric risk factors develop (i.e., delivery at <37 weeks' gestation, duration of membrane rupture ≥ 18 hours, or temperature $\geq 100.4^{\circ}\text{F}$ [$\geq 38.0^{\circ}\text{C}$]).
- Women with GBS bacteriuria in any concentration during their current pregnancy or who previously gave birth to an infant with GBS disease should receive intrapartum antimicrobial prophylaxis.
- In the absence of GBS urinary tract infection, antimicrobial agents should not be used before the intrapartum period to treat asymptomatic GBS colonization.

TABLE 1. Evidence-based rating system used to determine strength of recommendations

Category	Definition	Recommendation
Strength of recommendation		
A	Strong evidence for efficacy and substantial clinical benefit	Strongly recommended
B	Strong or moderate evidence for efficacy, but only limited clinical benefit	Generally recommended
C	Insufficient evidence for efficacy; or efficacy does not outweigh possible adverse consequences	Optional
D	Moderate evidence against efficacy or for adverse outcome	Generally not recommended
E	Strong evidence against efficacy or for adverse outcome	Never recommended
Quality of evidence supporting recommendation		
I	Evidence from at least one well-executed randomized, controlled trial or one rigorously designed laboratory-based experimental study that has been replicated by an independent investigator	
II	Evidence from at least one well-designed clinical trial without randomization; cohort or case-controlled analytic studies (preferably from more than one center); multiple time-series studies; dramatic results from uncontrolled studies; or some evidence from laboratory experiments	
III	Evidence from opinions of respected authorities based on clinical or laboratory experience, descriptive studies, or reports of expert committees	

Source: Adapted from CDC, 1999 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. MMWR 1999; 48(RR-10):1-66.

Background

Early Infancy and Pregnancy-Related Infections

GBS causes severe invasive disease in young infants. The majority of infections in newborns occur within the first week of life and are designated early-onset disease. Late-onset infections occur in infants aged >1 week, with most infections evident in the first 3 months of life. Young infants with invasive GBS disease usually present with sepsis or pneumonia, and less often contract meningitis, osteomyelitis, or septic arthritis. The proportion of infants with meningitis is higher among those with late-onset infections. When neonatal infections caused by GBS appeared in the 1970s, as many as 50% of patients died. During the 1990s, the case-fatality ratio of early- and late-onset disease was 4% (10) because of advances in neonatal care.

Intrauterine infection of the fetus results from ascending spread of GBS from the vagina of a colonized woman who is typically asymptomatic. Fetal aspiration of infected amniotic fluid can lead to stillbirth, neonatal pneumonia, or sepsis. Infants can also become infected with GBS during passage through the birth canal, although the majority of infants who are exposed to the organism through this route become colonized on skin or mucous membranes but remain asymptomatic.

In pregnant women, GBS can cause clinical infections, but most women have no symptoms associated with genital tract colonization. Urinary tract infections caused by GBS complicate 2%–4% of pregnancies (12,13). During pregnancy or the postpartum period, women can contract amnionitis, endometritis, sepsis, or rarely, meningitis caused by GBS (14–19). Fatalities among women with pregnancy-associated GBS disease are extremely rare.

GBS Colonization

The gastrointestinal tract serves as the natural reservoir for GBS and is the likely source of vaginal colonization. Vaginal colonization is unusual in childhood but becomes more common in late adolescence (20). Approximately 10% to 30% of pregnant women are colonized with GBS in the vagina or rectum (21). GBS colonization can be transient, chronic, or intermittent. Maternal intrapartum GBS colonization is a major risk factor for early-onset disease in infants, and vertical transmission of GBS from mother to fetus primarily occurs after the onset of labor or membrane rupture. However, colonization early in pregnancy is not predictive of neonatal sepsis (22). Culture screening of both the vagina and rectum for GBS late in gestation during prenatal care can

detect women who are likely to be colonized with GBS at the time of delivery and are thus at higher risk of perinatal transmission of the organism (23).

Classic epidemiologic studies conducted during the 1980s revealed that women with prenatal GBS colonization were >25 times more likely than women with negative prenatal cultures to deliver infants with early-onset GBS disease (24). Researchers used prenatal cultures as the basis for identifying candidates for intrapartum antimicrobial chemoprophylaxis; clinical trials identified reductions in vertical transmission of the organism, as measured by infant colonization (25,26) or by protection against early-onset disease (5,27). Heavy colonization, defined as culture of GBS from direct plating rather than only from selective broth, is associated with higher risk for early-onset disease. GBS identified in clean-catch urine specimens is considered a surrogate for heavy maternal colonization and also is associated with a higher risk for early-onset GBS disease (12,13); it has been included among indications for intrapartum antibiotic prophylaxis.

GBS Culture-Based Screening Methods

Numerous studies have documented that the accuracy of prenatal screening cultures in identifying intrapartum colonization status can be enhanced by careful attention to the timing of cultures, the anatomic sites swabbed, and the precise microbiologic methods used for culture and detection of organisms (Box 1). Collection of cultures between 35 and 37 weeks' gestation is recommended to improve the sensitivity and specificity of detection of women who remain colonized at the time of delivery (23,28). Swabbing both the lower vagina and rectum (i.e., through the anal sphincter) increases the yield substantially compared with sampling the cervix or sampling the vagina without also swabbing the rectum (29). Studies have indicated that when women in the outpatient clinic setting collect their own screening specimens, with appropriate instruction, GBS yield is similar to when specimens are collected by a health-care provider (30). Although swabbing both sites is recommended and use of two swabs can be justified, both swabs should be placed in a single broth culture medium because the site of isolation is not important for clinical management and laboratory costs can thereby be minimized. Because vaginal and rectal swabs are likely to yield diverse bacteria, use of selective enrichment broth is recommended (Box 1) to maximize the isolation of GBS and avoid overgrowth of other organisms. When direct agar plating is used instead of selective enrichment broth, as many as 50% of women who are GBS carriers have false-negative culture results (31).

BOX 1. Procedures for collecting and processing clinical specimens for group B streptococcal culture and performing susceptibility testing to clindamycin and erythromycin

Procedure for collecting clinical specimens for culture of group B streptococcus at 35–37 weeks' gestation

- Swab the lower vagina (vaginal introitus), followed by the rectum (i.e., insert swab through the anal sphincter) using the same swab or two different swabs. Cultures should be collected in the outpatient setting by the health-care provider or the patient herself, with appropriate instruction. Cervical cultures are not recommended and a speculum should not be used for culture collection.
- Place the swab(s) into a nonnutritive transport medium. Appropriate transport systems (e.g., Amies or Stuart's without charcoal) are commercially available. If vaginal and rectal swabs were collected separately, both swabs can be placed into the same container of medium. Transport media will maintain GBS viability for up to 4 days at room temperature or under refrigeration.
- Specimen labels should clearly identify that specimens are for group B streptococcal culture. If susceptibility testing is ordered for penicillin-allergic women (Box 2), specimen labels should also identify the patient as penicillin allergic and should specify that susceptibility testing for clindamycin and erythromycin should be performed if GBS is isolated.

Procedure for processing clinical specimens for culture of group B streptococcus

- Remove swab(s) from transport medium.* Inoculate swab(s) into a recommended selective broth medium, such as Todd-Hewitt broth supplemented with either gentamicin (8 µg/ml) and nalidixic acid (15 µg/ml), or with colistin (10 µg/ml) and nalidixic acid (15 µg/ml). Examples of appropriate commercially available options include Trans-Vag broth supplemented with 5% defibrinated sheep blood or LIM broth.†
- Incubate inoculated selective broth for 18–24 hours at 35°–37°C in ambient air or 5% CO₂. Subculture the broth to a sheep blood agar plate (e.g., tryptic soy agar with 5% defibrinated sheep blood).

- Inspect and identify organisms suggestive of GBS (i.e., narrow zone of beta hemolysis, gram-positive cocci, catalase negative). Note that hemolysis may be difficult to observe, so typical colonies without hemolysis should also be further tested. If GBS is not identified after incubation for 18–24 hours, reincubate and inspect at 48 hours to identify suspected organisms.
- Various streptococcus grouping latex agglutination tests or other tests for GBS antigen detection (e.g., genetic probe) may be used for specific identification, or the CAMP test may be employed for presumptive identification.

Procedure for clindamycin and erythromycin disk susceptibility testing of isolates, when ordered for penicillin-allergic patients§

- Use a cotton swab to make a suspension from 18–24-hour growth of the organism in saline or Mueller-Hinton broth to match a 0.5 McFarland turbidity standard.
- Within 15 minutes of adjusting the turbidity, dip a sterile cotton swab into the adjusted suspension. The swab should be rotated several times and pressed firmly on the inside wall of the tube above the fluid level. Use the swab to inoculate the entire surface of a Mueller-Hinton sheep blood agar plate. After the plate is dry, use sterile forceps to place a clindamycin (2 µg) disk onto half of the plate and an erythromycin (15 µg) disk onto the other half.
- Incubate at 35°C in 5% CO₂ for 20–24 hours.
- Measure the diameter of the zone of inhibition using a ruler or calipers. Interpret according to NCCLS guidelines for *Streptococcus* species other than *S. pneumoniae* (2002 breakpoints:§ clindamycin: ≥19 mm = susceptible, 16–18 = intermediate, ≤15 = resistant; erythromycin: ≥21 mm = susceptible, 16–20 = intermediate, ≤15 = resistant).

* Before inoculation step, some laboratories may choose to roll swab(s) on a single sheep blood agar plate or CNA sheep blood agar plate. This should be done only in addition to, and not instead of, inoculation into selective broth. The plate should be streaked for isolation, incubated at 35–37°C in ambient air or 5% CO₂ for 18–24 hours and inspected for organisms suggestive of GBS as described above. If suspected colonies are confirmed as GBS, the broth can be discarded, thus shortening the time to obtaining culture results.

† **Source:** Fenton, LJ, Harper MH. Evaluation of colistin and nalidixic acid in Todd-Hewitt broth for selective isolation of group B streptococci. *J Clin Microbiol* 1979;9:167–9. Although Trans-Vag medium is often available without sheep blood, direct comparison of medium with and without sheep blood has shown higher yield when blood is added. LIM broth may also benefit from the addition of sheep blood, although the improvement in yield is smaller and sufficient data are not yet available to support a recommendation.

§ **Source:** NCCLS. Performance standard for antimicrobial susceptibility testing, M100-S12, Table 2H, Wayne, Pa.: NCCLS, 2002. NCCLS recommends disk diffusion (M-2) or broth microdilution testing (M-7) for susceptibility testing of GBS. Commercial systems that have been cleared or approved for testing of streptococci other than *S. pneumoniae* may also be used. Penicillin susceptibility testing is not routinely recommended for GBS because penicillin-resistant isolates have not been confirmed to date.

Additional Risk Factors for Perinatal GBS Disease

In addition to colonization with GBS, other factors increase the risk for early-onset disease. These include gestational age <37 completed weeks, longer duration of membrane rupture, intraamniotic infection, young maternal age, black race, Hispanic ethnicity, and low maternal levels of anticapsular antibody (32–37). In a 1985 report of predictors of early-onset disease (24), women with gestation <37 weeks, membrane rupture of >12 hours, or intrapartum temperature >99.5°F (37.5°C) had 6.5 times the risk of having an infant with early-onset GBS disease compared with women with none of those factors. Of note, women who had one of these risk factors but who had negative prenatal screening cultures were at relatively low risk for early-onset GBS disease (attack rate 0.9 per 1,000 births) compared with women who were colonized prenatally but had none of the risk factors (attack rate 5.1 per 1,000 births) (24). In a risk-based strategy promoted during the 1990s as an alternative to prenatal culture-based screening approaches, prematurity (gestation <37 weeks), intrapartum fever (temperature $\geq 100.4^\circ\text{F}$ or 38°C), or duration of membrane rupture >18 hours were used as clinical indications for intrapartum prophylaxis. Previous delivery of an infant with invasive GBS disease may increase the risk of early-onset disease in subsequent deliveries (38,39), and intrapartum treatment of such women in subsequent pregnancies has been promoted. By contrast, colonization with GBS in a previous pregnancy is not considered an indication for intrapartum prophylaxis in subsequent pregnancies; rather, women require evaluation for prenatal colonization in each pregnancy. Because colonization is transient, the predictive value of culture-based screening is too low to be clinically useful when performed more than 5 weeks before delivery (28); thus, many women with GBS colonization during one pregnancy will no longer be colonized during subsequent pregnancies.

Impact and Implementation of the 1996 Guidelines

Declines in Perinatal GBS Disease Incidence in the Era of Chemoprophylaxis


Before the widespread use of intrapartum antibiotics, the incidence of invasive neonatal GBS disease ranged from 2 to 3 cases per 1,000 live births (9,40). Active, population-based surveillance in selected states in 1990, when GBS prevention was still rarely implemented, projected an incidence of 1.8

cases per 1,000 live births in the United States (early-onset disease: 1.5/1,000; late-onset: 0.35/1,000) (9).

Coinciding with active prevention efforts in the 1990s, the incidence of early-onset disease declined by 70% to 0.5 cases per 1,000 live births in 1999 (Figure 1). Projections from active surveillance data for 1999 from the Active Bacterial Core surveillance/Emerging Infections Program Network (ABCs)(41) estimate that intrapartum antibiotics prevented nearly 4,500 early-onset cases and 225 deaths that year (10,11). Other countries that have adopted perinatal GBS disease prevention guidelines similar to the United States have seen comparable declines in early-onset disease incidence (42–44). Recent estimates of early-onset disease incidence in the United States suggest a slight increase in incidence from 1999 to 2000, consistent with a plateau in the impact of prevention efforts (Figure 1).

The incidence of invasive GBS infections among pregnant women in the United States declined by 21% from 0.29 per 1,000 live births in 1993 to 0.23 in 1998 (10), suggesting that increased use of intrapartum antibiotics also prevented some cases of maternal GBS amnionitis and endometritis. In contrast, the rate of late-onset disease remained fairly constant throughout the 1990s (Figure 1). Although intrapartum chemoprophylaxis for women with heavy GBS colonization may prevent a portion of late-onset disease, the stable incidence of late-onset disease during a period when use of intrapartum antibiotics was increasing suggests that this intervention is not effective against late-onset disease.

FIGURE 1. Incidence of early- and late-onset invasive group B streptococcal disease—selected Active Bacterial Core surveillance areas, 1989–2000, and activities for prevention of group B streptococcal disease



* ACOG, American College of Obstetricians and Gynecologists; AAP, American Academy of Pediatrics. **Source:** Adapted from CDC. Early-onset group B streptococcal disease, United States, 1998–1999. *MMWR* 2000;49:793–6; and Schrag SJ, Zywicki S, Farley MM, et al. Group B streptococcal disease in the era of intrapartum antibiotic prophylaxis. *N Engl J Med* 2000;342:15–20.

Implementation of Chemoprophylaxis Strategies After the Release of the 1996 Guidelines

Declines in perinatal GBS disease incidence in the 1990s suggest that prevention strategies have been implemented successfully. Several studies have explored directly the challenges of implementation and extent of compliance with recommendations. Surveys of prenatal care providers in Connecticut and Minnesota in 1998 found that over 80% had a GBS prevention policy (Connecticut, 95%; Minnesota, 85%) (45). In Minnesota, family physicians were less likely to have a policy than were obstetrician/gynecologists and certified nurse midwives (45). A national survey of ACOG members in 2000 found that 98% of respondents had a GBS prevention policy; 75% of respondents reported using a version of the culture-based screening approach (46). Providers in all three surveys scored well on questions about their knowledge of the screening and risk-based strategies (45, 46).

In hospitals that established or revised policies for GBS prevention shortly after the release of the 1996 guidelines, rates of early-onset GBS disease declined by 1997 (47). By 1999, although only 63% of hospitals in a multistate survey of hospitals in the ABCs areas had a formal GBS prevention policy (48), having a hospital policy was no longer associated with changes in incidence of GBS disease, likely because a high proportion of individual practitioners had adopted policies by this time.

Several studies of single institutions or health maintenance organizations have evaluated adherence of hospital personnel to GBS guidelines (Table 2). Among hospitals with a risk-based policy, intrapartum antibiotics were administered in 40%–80% of preterm deliveries or deliveries with prolonged rupture of membranes (Table 2) (49–53). Among hospitals with a culture-based screening policy, close to 90% of delivering women had documented GBS screening, and close to 90% of GBS-positive women received intrapartum antibiotics (Table 2) (42, 51, 54–59).

Correct laboratory processing of culture specimens (Box 1) plays a critical role in successful implementation of the screening policy. A survey of clinical laboratories in selected counties of three states in 1997–1998 found that only a proportion of laboratories were using the recommended selective broth media to process GBS cultures (Georgia, 39% of laboratories; Minnesota, 42%; Connecticut, 62%), suggesting that this may be an area in need of improvement (31).

Although surveys of practitioners and laboratories and reports from single hospitals help monitor implementation of GBS prevention guidelines, a recent CDC-sponsored review of labor and delivery records in selected counties of eight states in the ABCs areas in 1998 and 1999 sheds light on actual provider practices 2 to 3 years after the release of the 1996 guidelines (60). In this population, GBS screening was documented in 52% of deliveries, although this varied widely, from 24% in selected counties of Oregon to 70% in Maryland.

TABLE 2. Institutional-level compliance with 1996 perinatal group B streptococcal disease prevention recommendations

Type of population sampled (ref.)	Deliveries receiving intrapartum antibiotics, %*	Deliveries with prolonged ROM* receiving intrapartum antibiotics, %*	Preterm deliveries receiving intrapartum antibiotics, %*	Women screened overall, %	GBS culture-positive women receiving intrapartum antibiotics, %*
Risk-based strategy evaluated					
2 HMO* hospitals, California (49)	–†	88	81	N/A†	N/A
University hospital, Florida (50)	–	20 in 1992 72 in 1995	13 in 1992 42 in 1995	N/A	N/A
Single hospital, Vienna, Austria (51)	11.9	–	–	N/A	N/A
Single hospital, Massachusetts (52)	–	81	–	N/A	N/A
Connecticut (statewide), 1996 (53)	15.2	45	53	N/A	N/A
Screening-based strategy evaluated					
Community hospital, New York (54)	–	N/A	76	91	86
University hospital, North Carolina (55)	12.9 for GBS prophylaxis	N/A	–	98	92
Single hospital, Sydney, Australia (42)	–	N/A	–	90	–
Single hospital, Vienna, Austria (51)	14.5	N/A	96	98.6	91
University hospital, New Mexico (56)	–	N/A	–	81	72
Single hospital, California (59)	26.3	N/A	91	89.8	94.4
Single hospital, Pennsylvania (57)	–	N/A	–	92	86
2 HMO hospitals, Washington State (58)	–	N/A	53	91	74 (automated data) 87 (chart review)
Single hospital, Massachusetts (52)	–	N/A	–	N/A	100
Connecticut (statewide), 1996 (53)	15.2	N/A	–	(36% of Connecticut births)	78

* Given for any reason.

† ROM, rupture of membranes; HMO, health maintenance organization; –, data not available; N/A, not applicable.

Among screened women, 24% were GBS positive, consistent with carriage rates reported in earlier studies; 89% of GBS-positive women received intrapartum antibiotics. The median time of GBS culture collection was at 35.6 weeks' gestation, consistent with the recommendation of 35–37 weeks' gestation. Among unscreened women, 24% had at least one intrapartum risk factor; however, only 61% of women with at least one risk factor received intrapartum antibiotics. Preterm delivery (<37 weeks' gestation) was the most common indication for which intrapartum antibiotics were not administered. Thus, this multistate record review confirmed trends in adherence identified in reports from single hospitals (Table 2).

Maximizing Prevention by Chemoprophylaxis

Effectiveness of the Risk-Based Approach Versus the Screening Approach

Despite dramatic declines in GBS incidence in the United States in the 1990s, GBS remains a leading cause of newborn morbidity and mortality, resulting in an estimated 1,600 early-onset cases and 80 deaths annually. Although alternatives to intrapartum antibiotics such as a vaccine may become available in the future, intrapartum chemoprophylaxis remains the most effective available intervention against perinatal GBS disease. However, debate about the most effective strategy for identifying candidates for intrapartum chemoprophylaxis continues.

When the 1996 guidelines were issued, data regarding the relative effectiveness of the risk-based and screening approaches were not available. Theoretical predictions based on population estimates of the proportion of early-onset GBS cases without obstetric risk factors (approximately 45% in the preprevention era [61]) suggested that the screening-based approach would lead to greater declines in disease incidence than the risk-based approach (61,62). However, because implementation of the risk-based approach has been viewed as simpler than the screening-based approach, which requires correct specimen collection at the prenatal clinic, appropriate laboratory processing, and timely reporting of results to delivery staff, the actual effectiveness of these strategies is unknown. Consequently, since 1996, both approaches have been recommended as equally acceptable pending further data (6–8).

Although observational data are now available suggesting that each strategy can lead to reduced incidence of early-onset GBS disease (49,50,63–65), the strategies have not been directly compared by clinical trial because of the large sample

size required. A series of single hospital analyses finding benefits of screening over the risk-based approach (51,56,59,66) were limited by sequential use of the strategies and inability to control for potential confounders. A recent CDC-sponsored multistate study provided the first large-scale direct comparison of the strategies (60). By incorporating population-based surveillance for early-onset GBS disease into a sample survey of a population of over 600,000 live births, this analysis found that the screening approach was >50% more effective than the risk-based approach at preventing perinatal GBS disease.

The protective effect of the screening approach was robust and persisted after controlling for risk factors associated with early-onset GBS disease (e.g., preterm delivery, prolonged membrane rupture, young maternal age, black race). The benefit of screening stemmed from two main factors. First, by identifying GBS-colonized women who did not present with obstetric risk factors, screening reached more of the population at risk than did the risk-based approach. Among the cohort of screened women, 18% of all deliveries were to mothers who were colonized with GBS but did not have obstetric risk factors. The efficacy of intrapartum antibiotics in preventing early-onset GBS disease among infants in this cohort was close to 90%, suggesting that chemoprophylaxis of GBS-positive women without obstetric risk factors resulted in significant prevention of early-onset disease.


Women who were GBS positive in the screening cohort were also more likely to receive intrapartum antibiotics than were women with obstetric risk factors in the risk cohort. Although improvements in implementation of the risk-based approach would lead to further decline in disease, this would not be as great as with universal screening (60).

Finally, because the effectiveness of screening in this study was based on actual implementation of this strategy in clinical practice in 1998 and 1999, further improvements in screening implementation (e.g., improvements in specimen collection and the methods used for processing cultures) are expected to result in further benefits.

Rationale for a Universal Prenatal Screening Strategy to Detect GBS Status

The new availability of category II evidence (Table 1) for a large protective effect of prenatal GBS screening compared with the risk-based approach provides the foundation for a recommendation of universal prenatal GBS screening (Figure 2). Statewide prevention activities in some ABCs areas further demonstrate that culture-based screening can be successfully implemented in a variety of settings and institutions. For example, a health department-led survey of clinical

FIGURE 2. Indications for intrapartum antibiotic prophylaxis to prevent perinatal GBS disease under a universal prenatal screening strategy based on combined vaginal and rectal cultures collected at 35–37 weeks' gestation from all pregnant women



* If onset of labor or rupture of amniotic membranes occurs at <37 weeks' gestation and there is a significant risk for preterm delivery (as assessed by the clinician), a suggested algorithm for GBS prophylaxis management is provided (Figure 3).

[†] If amnionitis is suspected, broad-spectrum antibiotic therapy that includes an agent known to be active against GBS should replace GBS prophylaxis.

laboratories in Connecticut followed by rapid feedback of survey results found that the proportion of laboratories in Connecticut using the correct media for processing GBS screening cultures increased from 62% in 1997 to 92% in 1998 (67) and 100% in 2000. Moreover, coinciding with an active prevention campaign launched by the state health department that advocated the screening-based approach, the incidence of early-onset GBS disease in Connecticut declined from 0.6 cases per 1,000 live births in 1996 (68) to 0.2 cases per 1,000 live births in 1999.

From the standpoint of implementation, universal screening has two additional benefits over the dual recommendations of 1996. Communication of the public health messages associated with a single strategy is simpler than communicating and educating about multiple strategies. Additionally, screening has clear indicators that facilitate evaluation of implementation (e.g., documentation of GBS test, timing of test, rates of GBS positivity) (58) compared with the risk-based approach, in which evidence of prevention implementation cannot be assessed for approximately 75% of deliveries because they have no intrapartum risk factors.

Cost-effectiveness analyses of the screening- and risk-based strategies (62,69–73) have indicated that although the initial costs associated with specimen collection and processing make the screening strategy more expensive than the risk-based

approach, the overall cost savings due to disease prevention do not differ importantly between strategies. Additionally, multistate review of labor and delivery records in 1998 and 1999 suggests that perfect implementation of the screening- or risk-based strategies will result in a comparable proportion of deliveries in which women receive intrapartum antibiotic prophylaxis for GBS (24% for both strategies) (60,74). Thus, the strategies cannot be distinguished in terms of the proportion of deliveries that will be exposed to intrapartum antibiotics.

Adverse Effects and Unintended Consequences of Chemoprophylaxis

Potential adverse or unintended effects of GBS prevention efforts that have raised concern include allergic or anaphylactic reactions to agents used for intrapartum antibiotic prophylaxis, emergence of GBS strains resistant to standard therapies, and increasing incidence of serious neonatal infections caused by pathogens other than GBS, including antimicrobial-resistant strains. Because of the increasing emergence of bacterial resistance to antimicrobial agents in both nosocomial and community settings, assessment of the impact and continued effectiveness of interventions based on antimicrobial prophylaxis is critical.

Antibiotic Allergies Including Anaphylaxis

Anaphylaxis associated with GBS chemoprophylaxis occurs but is sufficiently rare that any morbidity associated with anaphylaxis is greatly offset by reductions in the incidence of maternal and neonatal invasive GBS disease. Anaphylaxis-related mortality is likely to be a rare event since women receiving intrapartum antibiotics will be in hospital settings where rapid intervention is readily available. Estimates of the rate of anaphylaxis caused by penicillin range from 4/10,000 to 4/100,000 recipients. Additionally, as many as 10% of the adult population have less severe allergic reactions to penicillin (75). Anaphylaxis associated with GBS prophylaxis was reported in the early 1990s (76); since the release of the 1996 guidelines, an additional report of a nonfatal case of anaphylaxis associated with GBS chemoprophylaxis has been published (77). In a CDC multistate sample of over 5,000 live births, a single, nonfatal anaphylactic reaction was noted among the 27% of deliveries in which intrapartum antibiotics were administered (60). In that case, a single dose of penicillin was administered approximately 4 hours before a preterm cesarean delivery, and an anaphylactic reaction occurred shortly after the mother received a single dose of a cephalosporin following umbilical cord clamping.

Resistance in GBS

GBS isolates with confirmed resistance to penicillin or ampicillin have not been observed to date (78–83). Penicillin remains the agent of choice for intrapartum antibiotic prophylaxis. Ampicillin is an acceptable alternative, but penicillin is preferred because it has a narrower spectrum of antimicrobial activity and may be less likely to select for resistant organisms. The efficacy of both penicillin (27) and ampicillin (5) as intrapartum agents for the prevention of early-onset neonatal GBS disease has been demonstrated in clinical trials. Although the intramuscular route of administration for penicillin has been evaluated (25), intravenous administration is the only route of administration recommended for intrapartum chemoprophylaxis to prevent perinatal GBS disease, regardless of the antimicrobial agent used, because of the higher intraamniotic concentrations achieved with this method.

In contrast, the proportions of GBS isolates with *in vitro* resistance to clindamycin and erythromycin have increased since 1996. The prevalence of resistance among invasive GBS isolates in the United States and Canada ranged from 7% to 25% for erythromycin and from 3% to 15% for clindamycin in reports published between 1998 and 2001 (79–81,84). Resistance to erythromycin is frequently but not always associated with clindamycin resistance. Resistance of GBS isolates

to cefoxitin, a second-generation cephalosporin sometimes used as a component of broad-spectrum coverage for chorioamnionitis, has also been reported (85); cefoxitin resistance has similarly been observed among invasive GBS isolates collected from 1996 to 2000 as part of CDC's active surveillance. Whether *in vitro* resistance of GBS has direct clinical implications remains unclear (86). Despite emerging resistance to some drug classes, minimum inhibitory concentrations of cefazolin, a first-generation cephalosporin available in an intravenous formulation, were low (≤ 0.5 $\mu\text{g/ml}$) among a sample of invasive U.S. isolates from 1996 to 2000 (87), suggesting that GBS isolates are currently susceptible to this agent. Although NCCLS guidelines do not specify susceptibility breakpoints for cefazolin, they recommend that all isolates susceptible to penicillin be considered susceptible to cefazolin (88).

In light of the increasing prevalence of resistance to clindamycin, erythromycin, or both, recommended strategies for providing intrapartum antibiotic prophylaxis to penicillin-allergic women are updated (Box 2). Because the efficacy of recommended alternatives to penicillin or ampicillin has not been measured in controlled trials, and because some of the recommended alternatives have a broad spectrum of activity and may be more complicated and costly to administer, verification of a reported history of penicillin allergy is important. Patients with reported penicillin allergy should then be assessed to determine their risk for anaphylaxis. Persons at high risk for anaphylaxis are those who have had immediate hypersensitivity reactions to penicillin (e.g., anaphylaxis, angioedema, or urticaria) or who have a history of asthma or other conditions that would make anaphylaxis more dangerous (89,90). An estimated 10% of persons with penicillin allergy also have immediate hypersensitivity reactions to cephalosporins (90). Among penicillin-allergic women not at high risk for anaphylaxis, cefazolin, because of its narrow spectrum of activity and ability to achieve high intraamniotic concentrations, is the agent of choice for intrapartum chemoprophylaxis.

For penicillin-allergic women at high risk for anaphylaxis, testing of GBS isolates from prenatal screening for susceptibility to clindamycin and erythromycin is recommended if feasible (Box 1). One of these agents should be employed for intrapartum GBS prophylaxis if the screening isolate is susceptible to both agents.

Vancomycin should be reserved for penicillin-allergic women at high risk for beta-lactam anaphylaxis when clindamycin or erythromycin are not options because of *in vitro* resistance or unknown susceptibility of a prenatal isolate. Vancomycin use is generally restricted because of emerging vancomycin resistance among some gram-positive organisms (e.g., vancomycin-resistant enterococcus and vancomycin-resistant *Staphylococcus*

BOX 2. Recommended regimens for intrapartum antimicrobial prophylaxis for perinatal GBS disease prevention*

Recommended	Penicillin G, 5 million units IV initial dose, then 2.5 million units IV every 4 hours until delivery
Alternative	Ampicillin, 2 g IV initial dose, then 1 g IV every 4 hours until delivery
If penicillin allergic[†]	Cefazolin, 2 g IV initial dose, then 1 g IV every 8 hours until delivery
Patients not at high risk for anaphylaxis	
Patients at high risk for anaphylaxis [§]	Clindamycin, 900 mg IV every 8 hours until delivery
GBS susceptible to clindamycin and erythromycin [¶]	
	OR
	Erythromycin, 500 mg IV every 6 hours until delivery
GBS resistant to clindamycin or erythromycin or susceptibility unknown	Vancomycin,** 1 g IV every 12 hours until delivery

* Broader-spectrum agents, including an agent active against GBS, may be necessary for treatment of chorioamnionitis.

† History of penicillin allergy should be assessed to determine whether a high risk for anaphylaxis is present. Penicillin-allergic patients at high risk for anaphylaxis are those who have experienced immediate hypersensitivity to penicillin including a history of penicillin-related anaphylaxis; other high-risk patients are those with asthma or other diseases that would make anaphylaxis more dangerous or difficult to treat, such as persons being treated with beta-adrenergic-blocking agents.

§ If laboratory facilities are adequate, clindamycin and erythromycin susceptibility testing (Box 1) should be performed on prenatal GBS isolates from penicillin-allergic women at high risk for anaphylaxis.

¶ Resistance to erythromycin is often but not always associated with clindamycin resistance. If a strain is resistant to erythromycin but appears susceptible to clindamycin, it may still have inducible resistance to clindamycin.

** Cefazolin is preferred over vancomycin for women with a history of penicillin allergy other than immediate hypersensitivity reactions, and pharmacologic data suggest it achieves effective intraamniotic concentrations. Vancomycin should be reserved for penicillin-allergic women at high risk for anaphylaxis.

aureus). An estimated 13.8 million hospitalized patients received vancomycin therapy in 1998 (91). If penicillin allergy occurs in approximately 10% of adults, and 25% of parturients are colonized with GBS prenatally, approximately 100,000 of the 4 million annual deliveries would require prophylaxis with vancomycin in the absence of clindamycin and erythromycin susceptibility testing of GBS prenatal isolates. This represents a 7% increase in the number of patients exposed to vancomycin. The total grams of vancomycin used annually would increase by less than 1% if all penicillin-allergic colonized women received vancomycin prophylaxis.

Increased Incidence or Resistance in Non-GBS Pathogens

Decreases in the incidence of early-onset GBS sepsis have not usually been accompanied by increases in incidence of early-onset sepsis caused by other pathogens, including those that are antibiotic resistant. Most studies, including population-based multicenter studies, have found stable (59,92,93) or decreasing (43) rates of non-GBS early-onset sepsis during a period of increasing use of intrapartum antibiotic prophylaxis for GBS (Table 3). This is true both for overall non-GBS sepsis and for neonatal sepsis caused by *Escherichia coli*, the second leading bacterial cause of neonatal sepsis after GBS (93,94). Some single hospital studies have found increased rates or case counts of neonatal sepsis caused by *E. coli*, gram-negative organisms in general, or ampicillin-resistant pathogens (64,94,95), but these increases appear to be limited to preterm or low-birth-weight infants. An increasing proportion of *E. coli* neonatal sepsis cases caused by ampicillin-resistant organisms was observed in two studies (92,94), but again was limited to preterm or low-birth-weight infants. Furthermore, the proportion of community-acquired *E. coli* infections that are ampicillin resistant has been increasing (96), suggesting that trends in antimicrobial resistance should not be attributed to GBS prophylaxis.

An association between intrapartum antibiotic exposure and ampicillin resistance in cases of *E. coli* or other non-GBS early-onset sepsis has been observed in several studies (36,94,95,97,98). These reports established that infections caused by antibiotic-resistant organisms were more frequently preceded by antibiotic use than were infections caused by susceptible organisms, and that more doses or longer duration of antibiotics before delivery increased the chance that a neonatal infection, if it occurred, would be caused by an antibiotic-resistant organism. These studies, however, were not designed to assess whether intrapartum antibiotic use increased the rate of antibiotic-resistant infections. Moreover, findings from these studies are consistent with intrapartum antibiotics inducing

TABLE 3. Trends in neonatal sepsis incidence in the era of perinatal GBS disease prevention

Study site	Total births	Cause of early-onset sepsis	Number of cases (rate per 1,000 live births)						p-value
			1982–1987		1988–1993		1994–1999		
Illinois (1 hospital) (94)	61,498	<i>E. coli</i>	12 (0.37)	18 (0.62)					NS*
		<i>E. coli</i> (among low-birth-weight [†] infants)	2 (0.64)	8 (2.63)					0.05
California (1 hospital) (95)	29,897	GBS	5 (0.93)	3 (0.6)	2 (0.41)	2 (0.41)	2 (0.42)	1 (0.21)	NS
		Non-GBS	3 (0.56)	4 (0.8)	3 (0.61)	4 (0.81)	5 (1.04)	8 (1.65)	NS
		<i>E. coli</i>	0 (0)	1 (0.2)	1 (0.2)	2 (0.41)	2 (0.42)	5 (1.03)	0.001
Illinois (1 hospital) (64)	20,981	GBS	30 (1.7)	0 (0)					0.02
		All causes	– [§] (2.7)	– (2.1)					NS
		All gram negative	5 (0.29)	5 (1.3)					0.02
Connecticut (19 hospitals) (92)	140,923	GBS	20 (0.56)	17 (0.49)	20 (0.56)	8 (0.23)			0.01
		Non-GBS	24 (0.68)	23 (0.66)	24 (0.68)	23 (0.65)			NS
		<i>E. coli</i>	5 (0.14)	12 (0.35)	14 (0.39)	8 (0.23)			NS
Australia (multiple hospitals) (43)	172,947	GBS	33 (1.4)	68 (0.9)	27 (0.4)				<0.0001
		Non-GBS	30 (1.3)	63 (0.8)	29 (0.4)				<0.0001
California (1 hospital) (59)	29,403	GBS	8 (1.2)	15 (1.1)	0 (0)	2 (0.2)			0.001
		Non-GBS	11 (1.6)	14 (1.1)	7 (0.8)	6 (0.6)			NS
Ohio (1 hospital) (93)	41,738	GBS	24 (1.1)	11 (0.54)					0.04
		Non-GBS	28 (1.3)	29 (1.4)					NS

*NS = not statistically significant.

[†]Low birth weight defined as 1,501–2,500 g.[§]Data not available.

resistance among initially susceptible organisms, but also with intrapartum antibiotics preventing antibiotic-susceptible infections and having no impact on antibiotic-resistant infections, resulting in a net decrease in the total rate of infection.

The reported increases in antibiotic-resistant early-onset infections in a few studies are not of sufficient magnitude to outweigh the benefits of intrapartum antibiotic prophylaxis to prevent perinatal GBS disease. However, to assure early detection of increases in the rate of disease or deaths caused by organisms other than GBS, continued surveillance of neonatal sepsis caused by organisms other than GBS is needed.

Clinical Challenges

GBS Bacteriuria During Pregnancy

The presence of GBS bacteriuria in any concentration in a pregnant woman is a marker for heavy genital tract colonization. Therefore, women with any quantity of GBS bacteriuria

during pregnancy should receive intrapartum chemoprophylaxis. Vaginal and rectal screening at 35–37 weeks is not necessary for these women. GBS can cause both symptomatic and asymptomatic urinary tract infections, which should be diagnosed and treated according to current standards of care for urinary tract infections in pregnancy. Women with GBS urinary tract infections during pregnancy should receive appropriate treatment at the time of diagnosis as well as intrapartum GBS prophylaxis. Laboratory personnel should report any presence of GBS bacteriuria in specimens obtained from pregnant women. For this to occur, labeling of urine specimens to indicate that they were obtained from a pregnant woman is imperative.

Planned Cesarean Delivery

Because GBS can cross intact amniotic membranes, a cesarean delivery does not prevent mother-to-child transmission of GBS. Moreover, because cesarean delivery itself is associated with health risks for mother and newborn, GBS colonization of

the mother is not an indication for cesarean delivery, and cesarean delivery should not be used as an alternative to intrapartum antibiotic prophylaxis for GBS prevention.

However, although a risk does exist for transmission of GBS from a colonized mother to her infant during a planned cesarean delivery performed before onset of labor in a woman with intact amniotic membranes, it is extremely low, based on a retrospective study at a single hospital (99) and a review of CDC active, population-based surveillance data from the 1990s. Thus, in this specific circumstance, in which the risk for disease is extremely low, the individual risks to a mother and her infant from receiving intrapartum antibiotic prophylaxis may balance or outweigh the benefits. Intrapartum antibiotic prophylaxis to prevent perinatal GBS disease is, therefore, not recommended as a routine practice for women undergoing planned cesarean deliveries in the absence of labor or amniotic membrane rupture, regardless of the GBS colonization status of the mother. Patients expected to undergo planned cesarean deliveries should nonetheless still undergo routine vaginal and rectal screening for GBS at 35–37 weeks because onset of labor or rupture of membranes may occur before the planned cesarean delivery. In rare situations in which patients or providers opt for intrapartum prophylaxis before planned cesarean deliveries, administration of antibiotics at the time of incision rather than at least 4 hours before delivery may be reasonable (100).

Threatened Preterm Delivery


Because preterm (at <37 weeks' gestation) delivery is an important risk factor for early-onset GBS disease, and because timing of delivery can be difficult to assess, management of intrapartum prophylaxis for women with threatened preterm delivery can be challenging. Assessing the need for intrapartum prophylaxis for these women can also be difficult because GBS screening is recommended at 35 to 37 weeks' gestation, and culture results are not always available when labor or rupture of membranes occur preterm.

A suggested approach to GBS chemoprophylaxis in the context of threatened preterm delivery is outlined (Figure 3). Because insufficient data are available to suggest a single course of management, other management strategies developed

by individual physicians or institutions may be appropriate alternatives. The algorithm suggests that if GBS screening culture results from the current pregnancy are not available and if onset of labor or rupture of membranes occurs before 37 weeks' gestation with a substantial risk for preterm delivery (as assessed by the woman's health-care provider), intrapartum antibiotic prophylaxis for GBS should be provided pending culture results. For women not yet screened for GBS, a vaginal and rectal specimen for GBS culture should be obtained if time permits. If a negative culture result within the previous 4 weeks is on record, or if the clinician determines that labor can be successfully arrested and preterm delivery averted, antibiotics for GBS prophylaxis should not be initiated. Because recent clinical trials suggest that antibiotics administered during pregnancy may be associated with adverse neonatal outcomes, such as necrotizing enterocolitis or increased need for supplementary oxygen, without evident benefit for preterm labor or preterm premature rupture of membranes (101,102), antibiotics should be reserved for instances in which a significant risk for preterm delivery is present.

No data are available on which to recommend a specific duration of antibiotic administration for GBS-positive women with threatened preterm delivery when delivery is successfully postponed. Management strategies based on scientific opinion

FIGURE 3. Sample algorithm for GBS prophylaxis for women with threatened preterm delivery. This algorithm is not an exclusive course of management. Variations that incorporate individual circumstances or institutional preferences may be appropriate.



* Penicillin should be continued for a total of at least 48 hours, unless delivery occurs sooner. At the physician's discretion, antibiotic prophylaxis may be continued beyond 48 hours in a GBS culture-positive woman if delivery has not yet occurred. For women who are GBS culture positive, antibiotic prophylaxis should be reinitiated when labor likely to proceed to delivery occurs or recurs.

† If delivery has not occurred within 4 weeks, a vaginal and rectal GBS screening culture should be repeated and the patient should be managed as described, based on the result of the repeat culture.

§ Intrapartum antibiotic prophylaxis.

have been proposed (100); without further data, the management approach is left to the discretion of the individual provider. Regardless of management strategy chosen, these women should also receive intrapartum antibiotic chemoprophylaxis for GBS when labor likely to proceed to delivery occurs or recurs.

Previous data (28) suggest that the accuracy of GBS screening cultures in predicting colonization status at delivery is greatest if the cultures are collected within 5 weeks of delivery. Therefore, if a woman is screened early for GBS because of threatened preterm delivery but does not deliver within 4 weeks, she should be screened again for GBS colonization and managed according to the result of the repeated screening culture (Figure 3).

Obstetric Procedures for GBS-Colonized Women

Questions have arisen regarding whether certain obstetric procedures, such as digital vaginal examinations, intrauterine fetal monitoring, and membrane stripping or sweeping to hasten the onset of labor, should be performed on GBS-colonized women. Asymptomatic GBS colonization is not an indication to perform any of these procedures. When such procedures are indicated for other reasons, evidence is currently not sufficient to recommend that particular procedures should be avoided because of increased risk of peripartum or perinatal infection. Although some obstetric procedures (frequent vaginal examinations after onset of labor or membrane rupture [17,36,103–105], intrauterine fetal monitoring [104,106,107], and mechanical cervical ripening devices [108]) have been significantly associated with peripartum or perinatal infectious outcomes, most studies to date have been limited by an inability to randomly allocate women to treatment groups and have yielded conflicting results. Moreover, because many studies were performed before GBS prevention was widely implemented, GBS colonization status was often not known and intrapartum chemoprophylaxis was less common. A meta-analysis of available studies examining the use of membrane stripping among women of undetermined GBS colonization status (109) found no significant increases in overall peripartum or perinatal infection rates among women who underwent this procedure and their infants compared with those who did not.


Management of Newborns Exposed to Intrapartum Prophylaxis

On the basis of information available since the publication of the 1996 guidelines, a modified approach for empiric management of newborns born to women who receive

intrapartum antibiotics to prevent early-onset GBS disease or to treat suspected chorioamnionitis is provided (Figure 4). Variations in the algorithm that incorporate individual circumstances or institutional preferences may be appropriate. The modified approach contains the following changes:

- If a woman receives intrapartum antibiotics for treatment of suspected chorioamnionitis, her newborn should have a full diagnostic evaluation and empiric therapy pending

FIGURE 4. Sample algorithm for management of a newborn whose mother received intrapartum antimicrobial agents for prevention of early-onset group B streptococcal disease* or suspected chorioamnionitis. This algorithm is not an exclusive course of management. Variations that incorporate individual circumstances or institutional preferences may be appropriate.



* If no maternal intrapartum prophylaxis for GBS was administered despite an indication being present, data are insufficient on which to recommend a single management strategy.

† Includes complete blood cell count and differential, blood culture, and chest radiograph if respiratory abnormalities are present. When signs of sepsis are present, a lumbar puncture, if feasible, should be performed.

§ Duration of therapy varies depending on results of blood culture, cerebrospinal fluid findings, if obtained, and the clinical course of the infant. If laboratory results and clinical course do not indicate bacterial infection, duration may be as short as 48 hours.

¶ CBC with differential and blood culture.

** Applies only to penicillin, ampicillin, or cefazolin and assumes recommended dosing regimens (Box 2)

†† A healthy-appearing infant who was ≥38 weeks' gestation at delivery and whose mother received ≥4 hours of intrapartum prophylaxis before delivery may be discharged home after 24 hours if other discharge criteria have been met and a person able to comply fully with instructions for home observation will be present. If any one of these conditions is not met, the infant should be observed in the hospital for at least 48 hours and until criteria for discharge are achieved.

culture results, regardless of clinical condition at birth, duration of maternal antibiotic therapy before delivery, or gestational age at delivery (110). Empiric therapy for the infant should include antimicrobial agents active against GBS as well as other organisms that might cause neonatal sepsis (e.g., ampicillin and gentamicin).

- When clinical signs in the infant suggest sepsis, a full diagnostic evaluation should include a lumbar puncture, if feasible. Blood cultures can be sterile in as many as 15% of newborns with meningitis (111–113), and the clinical management of an infant with abnormal cerebrospinal fluid (CSF) findings differs from that of an infant with normal CSF. If a lumbar puncture has been deferred for a neonate receiving empiric antibiotic therapy, and the therapy is continued beyond 48 hours because of clinical instability, CSF should be obtained for cell count, glucose, protein, and culture.
- In addition to penicillin or ampicillin, initiation of intrapartum antibiotic prophylaxis with cefazolin at least 4 hours before delivery can be considered adequate, based on achievable amniotic fluid concentrations of cefazolin (114). Although other agents may be substituted for penicillin if the woman has a history of penicillin allergy (Box 2), the effectiveness of these agents in preventing early-onset GBS disease has not been studied and no data are available to suggest the durations before delivery of these regimens that can be considered adequate.
- Based on the demonstrated effectiveness of intrapartum antibiotic prophylaxis at preventing early-onset GBS disease (65) and data indicating that clinical onset occurs within the first 24 hours of life in over 90% of infants who contract early-onset GBS disease (115), hospital discharge as early as 24 hours after delivery may be reasonable under certain circumstances. Specifically, a healthy-appearing infant who is ≥ 38 weeks' gestation at delivery and whose mother received ≥ 4 hours of intrapartum antibiotic prophylaxis before delivery may be discharged home as early as 24 hours after delivery, assuming that other discharge criteria have been met and that a person able to comply fully with instructions for home observation will be present. A key component of following instructions is the ability of the person observing to communicate with health-care providers by telephone and to transport the child promptly to an appropriate health-care facility if clinical signs of sepsis develop. If these conditions are not met, the infant should remain in the hospital for at least 48 hours of observation and until criteria for discharge are achieved.

Investigations since 1996 lend additional support to several components of the algorithm. A retrospective study of over 250,000 live births (115) found that administration of intrapartum antibiotic prophylaxis did not change the clinical spectrum of neonatal illness or delay the onset of clinical signs among infants who contracted GBS disease despite prophylaxis. Thus, the algorithm targets infants born to mothers with suspected chorioamnionitis and infants with signs of sepsis for full diagnostic evaluation and empiric therapy. Also, new evidence indicates that 4 or more hours of intrapartum ampicillin or penicillin administered according to recommended dosing intervals (Box 2) significantly reduces vertical transmission of GBS (116) and risk of early-onset GBS disease (65). Thus, although the American Academy of Pediatrics 1997 guidelines suggested 2 or more doses as a threshold for prophylaxis adequacy for infants ≥ 35 weeks' gestation (8), the revised algorithm continues to use ≥ 4 hours, administered according to recommended dosing intervals, as the benchmark for optimal prevention of early-onset GBS disease. Moreover, a review of pregnancies at a West Coast health maintenance organization using the GBS culture-based screening strategy found that among women who received intrapartum antibiotic prophylaxis, 50% received prophylaxis at least 4 hours before delivery, whereas only 14% received at least 2 doses of intrapartum antibiotics (58); this indicates that duration of prophylaxis is a more practical target than number of doses, in addition to being associated with efficacy.

One objective of developing an algorithm for management of newborns was to minimize unnecessary evaluation and antimicrobial treatment of infants whose mothers received intrapartum prophylaxis. Although early provider surveys indicated that pediatricians and neonatologists were more likely to conduct diagnostic evaluations and initiate empiric antibiotics for an infant whose mother received intrapartum antibiotic prophylaxis (117–119), more recent data indicate that implementation of GBS prevention strategies has not resulted in increased use of health services for neonates (120), and in some circumstances, when GBS prophylaxis increased a decrease occurred in the proportion of neonates who received laboratory evaluations (58).

Intrapartum antibiotic prophylaxis is the method of choice for preventing neonatal early-onset GBS disease. In the event that intrapartum antibiotics are not given despite an indication (e.g., delivery occurred precipitously before antibiotics could be administered to a GBS-positive woman), sufficient data are not available on which to recommend a single management strategy for the newborn. Some centers provide intramuscular penicillin to asymptomatic infants within 1 hour of birth, based on results of observational studies showing

declines in early-onset GBS disease coincident with a policy of universal administration of intramuscular penicillin to all newborns (121).

Future Prevention Technology

Rapid Tests to Detect GBS Colonization Status

Rapid tests for detection of GBS colonization at the time of onset of labor or rupture of amniotic membranes might obviate the need for prenatal culture-based screening if their sensitivity and specificity are comparable to culture in selective broth media and they yield results rapidly enough to permit administration of adequate intrapartum antibiotic prophylaxis to women detected as carriers. Currently available rapid tests detect GBS antigen from swab specimens. These tests are insufficiently sensitive to detect light colonization, and therefore are not adequate to replace culture-based prenatal screening (122,123) or to use in place of the risk-based approach when culture results are unknown at the time of labor. An adequate rapid intrapartum test must be as sensitive as culture (minimally 85% compared with culture of vaginal and rectal swabs inoculated into selective broth media), rapid so that results are available to clinicians in time for antibiotics to be given before delivery, and convenient for integration into routine laboratory use. Even a highly sensitive rapid detection test would not be adequate if results were not available to clinicians 24 hours a day, 7 days a week. Alternatives to culturing vaginal and rectal swab specimens at 35–37 weeks' gestation using recommended procedures should be validated to show sensitivity similar to recommended culture methods.

A rapid intrapartum test possessing the attributes described above offers the advantage of ascertaining GBS colonization status before delivery among women who have had no prenatal care. Although such tests might initially be introduced selectively in certain facilities with sufficient demand and capability, a general recommendation for their use would require the capacity for effective implementation in a wide range of hospital settings. Drawbacks of rapid tests include delays in administration of intrapartum antibiotic prophylaxis while test results are pending and lack of an isolate for susceptibility testing, which is of particular concern for penicillin-allergic women. Additionally, until rapid tests are universally used, missed opportunities for GBS screening may occur among women who receive prenatal care at institutions relying on intrapartum rapid tests but who deliver at institutions where such tests are not yet available.

In a study of 112 pregnant women at an academic hospital in Quebec, a new, not yet commercially available fluorogenic polymerase chain reaction assay was 97% sensitive and 100% specific when compared with vaginal and rectal cultures collected at admission for delivery. Test results in this study were available within 45 minutes of specimen collection (124). Further studies are needed to determine whether this type of test can be adapted for use outside the research setting. If appropriate techniques for rapid detection of GBS become commercially available, they may be integrated into the currently recommended screening strategy.

Vaccines To Prevent GBS Disease

Improved use of intrapartum antimicrobial prophylaxis has resulted in a substantial reduction in early-onset GBS disease, but it is unlikely to prevent most late-onset neonatal infections, GBS-related stillbirths, or prematurity, and does not address GBS disease in nonpregnant adults. Immunization of women during or before pregnancy could prevent peripartum maternal disease and protect infants from perinatally acquired infection by transplacental transfer of protective IgG antibodies (125,126). This would eliminate the need for prenatal GBS screening and intrapartum antimicrobial prophylaxis, along with associated costs and concerns regarding the potential adverse effects of intrapartum antibiotic use discussed previously.

Serotype-specific antibodies to GBS capsular polysaccharide, although rare in populations of unvaccinated women, have been shown to protect against disease (32,127). Phase 1 and 2 clinical trials among healthy, nonpregnant adults of monovalent protein-conjugate vaccines containing capsular polysaccharide antigens of GBS disease-associated serotypes have shown these vaccines to be well tolerated and immunogenic (128–130). One challenge of demonstrating vaccine efficacy in preventing early-onset GBS disease is that the sample size required for clinical trials may be prohibitively large. Identification of surrogate immunologic measures of clinical efficacy may thus be important (131,132). Surrogate information on clinical vaccine efficacy may also be gained by measuring the impact of multivalent conjugate vaccines on vaginal GBS colonization (132,133).

Anticipated difficulties in making vaccine available to pregnant women have resulted in consideration of other target populations for vaccine administration, including adolescent girls (134), women of childbearing age, and infants (135). The duration of protection that could be afforded by vaccination is unknown; one or more booster doses might be required, potentially complicating vaccine delivery. Shifts in the GBS serotypes causing disease have provided an additional

challenge to vaccine development (133) and may necessitate modification of vaccine serotype composition over time.

Research Priorities and Tools To Aid Prevention

Technological advances that aid the implementation of a universal screening strategy will further prevention efforts. In addition to development of reliable rapid tests that can be performed in a wide range of labor and delivery settings, methods of simplifying prenatal culture procedures, e.g., the development of media with a reliable color indicator to signal presence of GBS, might improve accuracy of prenatal culture results and facilitate prenatal culture processing at clinical laboratories with limited technical capacity. Media that have been developed for this purpose, such as Granada (136,137) or GBS medium (138), should be further evaluated to determine if sensitivity and specificity are comparable to recommended methods, which consist of culture in selective broth media followed by GBS-specific identification.

Although universal prenatal GBS culture-based screening is likely to result in substantial further declines in the incidence of early-onset disease, intrapartum chemoprophylaxis is not a permanent or comprehensive strategy for GBS disease prevention. Because vaccines under development hold promise to prevent a larger portion of the burden of GBS disease with a simpler and sustainable intervention, further work on GBS vaccine development and support of phase 3 clinical trials are warranted (139).

Until a safe, effective, and economical vaccine achieves licensure, it will be important to continue to monitor for potential adverse effects of chemoprophylaxis, with an emphasis on tracking key sentinel events signaling a need for revision of the guidelines. Such sentinel events include the emergence of penicillin resistance among GBS, which to date has not been detected, and an increase in the incidence of disease or deaths due to neonatal pathogens other than GBS that offsets the burden of early-onset disease prevented by chemoprophylaxis. Monitoring for the latter will require long-term surveillance of a large population of term and preterm births (140).

Because GBS carriage is common among delivering women in the United States, continued surveillance for GBS disease and evaluation of prevention implementation remains important to minimize missed opportunities for prevention. States are encouraged to monitor incidence of GBS disease, to promote activities that enhance perinatal GBS disease prevention and education, and to assess progress toward national objectives for disease reduction, such as Healthy People 2010,

which sets a target of reducing the incidence of early-onset GBS disease in all racial and ethnic groups to 0.5 cases per 1,000 live births (141). Practical tools to assist with monitoring for missed opportunities for perinatal GBS prevention within hospitals have been published (142); additional prevention information and tools for providers, patients and clinical microbiologists are available at <http://www.cdc.gov/groupbstrep>, <http://www.acog.org>, <http://sales.acog.com>, <http://www.aap.org>, and <http://www.health.state.mn.us/divs/dpc/ades/invbact/strepb.htm>.

Recommendations

The following updated recommendations for the prevention of GBS disease are based on critical appraisal of multistate population-based observational data and several studies from individual institutions that have been completed since publication of previous CDC (7), ACOG (6), and AAP (8) recommendations. They replace previous recommendations from CDC. The strength (indicated by a letter) and quality (indicated by a roman numeral) of evidence supporting each recommendation are shown in parentheses, according to the evidence-based rating system outlined in Table 1.

Obstetric-care practitioners, in conjunction with supporting laboratories and labor and delivery facilities, should adopt the following strategy for the prevention of perinatal GBS disease based on prenatal screening for GBS colonization. The risk-based approach is no longer an acceptable alternative except for circumstances in which screening results are not available before delivery (AII).

- All pregnant women should be screened at 35–37 weeks' gestation for vaginal and rectal GBS colonization (Figure 2) (AII). At the time of labor or rupture of membranes, intrapartum chemoprophylaxis should be given to all pregnant women identified as GBS carriers (AII). Colonization during a previous pregnancy is not an indication for intrapartum prophylaxis in subsequent deliveries. Screening to detect GBS colonization in each pregnancy will determine the need for prophylaxis in that pregnancy.
- Women with GBS isolated from the urine in any concentration (e.g., 10^3) during their current pregnancy should receive intrapartum chemoprophylaxis because such women usually are heavily colonized with GBS and are at increased risk of delivering an infant with early-onset GBS disease (BII). Labels on urine specimens from prenatal patients should clearly state the patient's pregnancy status to assist laboratory processing and reporting of results. Prenatal culture-based screening at 35–37 weeks' gestation is not necessary for women with GBS bacteriuria. Women with symptomatic or asymptomatic GBS urinary

tract infection detected during pregnancy should be treated according to current standards of care for urinary tract infection during pregnancy.

- Women who have previously given birth to an infant with invasive GBS disease should receive intrapartum chemoprophylaxis; prenatal culture-based screening is not necessary for these women (BII).
- If the result of GBS culture is not known at the onset of labor, intrapartum chemoprophylaxis should be administered to women with any of the following risk factors: gestation <37 weeks, duration of membrane rupture ≥ 18 hours, or a temperature of $\geq 100.4^\circ\text{F}$ ($\geq 38.0^\circ\text{C}$) (AII). Women with known negative results from vaginal and rectal GBS screening cultures within 5 weeks of delivery do not require prophylaxis to prevent GBS disease even if any of the intrapartum risk factors develop.
- Women with threatened preterm (<37 weeks' gestation) delivery should be assessed for need for intrapartum prophylaxis to prevent perinatal GBS disease. An algorithm for management of women with threatened preterm delivery is provided (Figure 3). Other management approaches, developed by individual physicians or institutions, may be appropriate (CIII).
- Culture techniques that maximize the likelihood of GBS recovery are required for prenatal screening (Box 1). Collection of specimens for culture may be conducted in the outpatient clinic setting by either the patient, with appropriate instruction, or health-care provider (BII). This involves swabbing the lower vagina and rectum (i.e., through the anal sphincter). Because lower vaginal as opposed to cervical cultures are recommended, cultures should not be collected by speculum examination. Specimens should be placed in a nonnutritive transport medium (e.g., Amies or Stuart's without charcoal). Specimen labels should clearly identify that specimens are for group B streptococcal culture. If susceptibility testing is ordered for penicillin-allergic women (Box 2), specimen labels should also identify the patient as penicillin allergic and should specify that if GBS is isolated, it should be tested for susceptibility to clindamycin and erythromycin. Specimens should be inoculated into a selective broth medium (examples of appropriate commercially available media include Trans-Vag Broth supplemented with 5% defibrinated sheep blood or LIM broth), incubated overnight, and subcultured onto solid blood agar medium (AII). Methods of testing prenatal isolates from penicillin-allergic women for susceptibility to clindamycin and erythromycin are outlined (Box 1). Laboratories should report culture results (positive and negative) and susceptibility

testing results to the anticipated site of delivery (when known) and to the health-care provider who ordered the test.

- Health-care providers should inform women of their GBS screening test result and the recommended interventions. In the absence of GBS urinary tract infection, antimicrobial agents should not be used before the intrapartum period to treat GBS colonization. Such treatment is not effective in eliminating carriage or preventing neonatal disease and may cause adverse consequences (DI).
- GBS-colonized women who have a planned cesarean delivery performed before rupture of membranes and onset of labor are at low risk for having an infant with early-onset GBS disease. These women should not routinely receive intrapartum chemoprophylaxis for perinatal GBS disease prevention (CII).
- For intrapartum chemoprophylaxis, the following regimen is recommended for women without penicillin allergy (Box 2): penicillin G, 5 million units intravenously initial dose, then 2.5 million units intravenously every 4 hours until delivery (AII). Because of its narrow spectrum of activity, penicillin is the preferred agent. An alternative regimen is ampicillin, 2 g intravenously initial dose, then 1 g intravenously every 4 hours until delivery (AI).
- Intrapartum chemoprophylaxis for penicillin-allergic women takes into account increasing resistance to clindamycin and erythromycin among GBS isolates (Box 2). During prenatal care, history of penicillin allergy should be assessed to determine whether a patient is at high risk for anaphylaxis, i.e., has a history of immediate hypersensitivity reactions to penicillin (e.g., anaphylaxis, angioedema, or urticaria) or history of asthma or other conditions that would make anaphylaxis more dangerous (89). Women who are not at high risk for anaphylaxis should be given cefazolin, 2 g intravenously initial dose, then 1 g intravenously every 8 hours until delivery (BIII). For women at high risk for anaphylaxis, clindamycin and erythromycin susceptibility testing, if available, should be performed on isolates obtained during GBS prenatal carriage screening. Women with clindamycin- and erythromycin-susceptible isolates should be given either clindamycin, 900 mg intravenously every 8 hours until delivery; OR erythromycin, 500 mg intravenously every 6 hours until delivery. If susceptibility testing is not possible, susceptibility results are not known, or isolates are resistant to erythromycin or clindamycin, the following regimen can be used for women with immediate penicillin hypersensitivity: vancomycin, 1 g intravenously every 12 hours until delivery (CIII).

- Routine use of antimicrobial prophylaxis for newborns whose mothers received intrapartum chemoprophylaxis for GBS infection is not recommended. However, therapeutic use of these agents is appropriate for infants with clinically suspected sepsis. An updated algorithm for management of infants born to mothers who received intrapartum chemoprophylaxis for GBS infection is provided (Figure 4). This revised algorithm is not an exclusive approach to management; variation that incorporates individual circumstances or institutional preferences may be appropriate (CIII).
- Local and state public health agencies, in conjunction with appropriate groups of hospitals, are encouraged to establish surveillance for early-onset GBS disease and to take other steps to promote perinatal GBS disease prevention and education to reduce the incidence of early-onset GBS disease in their states. Efforts to monitor the emergence of perinatal infections caused by other organisms are also encouraged.

Before full implementation of this strategy can be expected in all health-care settings, all members of the health-care team will need to improve protocols for isolation and reporting of GBS culture results, to improve information management to ensure communication of screening results, and to educate medical and nursing staff responsible for prenatal and intrapartum care. Within institutions, such efforts may take several months.

Even with ideal implementation, cases of early-onset GBS disease will continue to occur. Tools to help promote prevention and educate parents of infants with early-onset GBS disease are available at <http://www.cdc.gov/groupbstrep>. Additional tools available to assist with prevention implementation are available at <http://www.acog.org>, <http://sales.acog.com>, <http://www.aap.org> and <http://www.health.state.mn.us/divs/dpc/ades/invbact/strepb.htm>. Multiple copies of educational materials published by CDC are available at the Public Health Foundation, 1220 L St., NW Suite 350, Washington, DC 20005, telephone 877-252-1200, or online at <http://www.phf.org>.

References

1. Baker CJ, Barrett FF, Gordon RC, Yow MD. Suppurative meningitis due to streptococci of Lancefield group B: a study of 33 infants. *J Pediatr* 1973;82:724-9.
2. Barton LL, Feigin RD, Lins R. Group B beta hemolytic streptococcal meningitis in infants. *J Pediatr* 1973;82:719-23.
3. Franciosi RA, Knostman JD, Zimmerman RA. Group B streptococcal neonatal and infant infections. *J Pediatr* 1973;82:707-18.
4. McCracken GH. Group B streptococci: the new challenge in neonatal infections. *J Pediatr* 1973;82:703-6.
5. Boyer KM, Gotoff SP. Prevention of early-onset neonatal group B streptococcal disease with selective intrapartum chemoprophylaxis. *N Engl J Med* 1986;314:1665-9.
6. American College of Obstetricians and Gynecologists, Committee on Obstetric Practice. Prevention of early-onset group B streptococcal disease in newborns [Opinion 173]. Washington, D. C.: American College of Obstetricians and Gynecologists, 1996.
7. CDC. Prevention of perinatal group B streptococcal disease: a public health perspective. *MMWR* 1996;45 (RR-7):1-24.
8. American Academy of Pediatrics, Committee on Infectious Diseases/Committee on Fetus and Newborn. Revised guidelines for prevention of early-onset group B streptococcal (GBS) disease. *Pediatrics* 1997;99:489-96.
9. Zangwill KM, Schuchat A, Wenger JD. Group B streptococcal disease in the United States, 1990: report from a multistate active surveillance system. *MMWR* 1992;41(SS-6):25-32.
10. Schrag SJ, Zywicki S, Farley MM, et al. Group B streptococcal disease in the era of intrapartum antibiotic prophylaxis. *N Engl J Med* 2000;342:15-20.
11. CDC. Early-onset group B streptococcal disease, United States, 1998-1999. *MMWR* 2000;49:793-6.
12. Persson K, Christensen KK, Christensen P, Forsgren A, Jorgensen C, Persson PH. Asymptomatic bacteriuria during pregnancy with special reference to group B streptococci. *Scand J Infect Dis* 1985;17:195-9.
13. Wood EG, Dillon HC. A prospective study of group B streptococcal bacteriuria in pregnancy. *Am J Obstet Gynecol* 1981;140:515-20.
14. Pass MA, Gray BM, Dillon HC. Puerperal and perinatal infections with group B streptococci. *Am J Obstet Gynecol* 1982;143:147-52.
15. Bobitt JR, Ledger WJ. Amniotic fluid analysis: its role in maternal and neonatal infection. *Obstet Gynecol* 1978;51:56-62.
16. Braun TI, Pinover W, Sih P. Group B streptococcal meningitis in a pregnant woman before the onset of labor. *Clin Infect Dis* 1995;21:1042-3.
17. Yancey MK, Duff P, Clark P, Kurtzer T, Frentzen BH, Kubilis P. Peripartum infection associated with vaginal group B streptococcal colonization. *Obstet Gynecol* 1994;84:816-9.
18. Fox BC. Delayed-onset postpartum meningitis due to group B streptococcus [letter]. *Clin Infect Dis* 1994;19:350.
19. Aharoni A, Potasman I, Levitan Z, Golan D, Sharf M. Postpartum maternal group B streptococcal meningitis. *Rev Infect Dis* 1990;12:273-6.
20. Hammerschlag MR, Baker CJ, Alpert S, et al. Colonization with group B streptococci in girls under 16 years of age. *Pediatrics* 1977;60:473-6.
21. Regan JA, Klebanoff MA, Nugent RP, Vaginal Infections and Prematurity Study Group. The epidemiology of group B streptococcal colonization in pregnancy. *Obstet Gynecol* 1991;77:604-10.
22. Regan JA, Klebanoff MA, Nugent RP, et al. Colonization with group B streptococci in pregnancy and adverse outcome. *Am J Obstet Gynecol* 1996;174:1354-60.
23. Boyer KM, Gadzala CA, Kelly PD, Burd LI, Gotoff SP. Selective intrapartum chemoprophylaxis of neonatal group B streptococcal early-onset disease. II. Predictive value of prenatal cultures. *J Infect Dis* 1983;148:802-9.
24. Boyer KM, Gotoff SP. Strategies for chemoprophylaxis of GBS early-onset infections. *Antibiot Chemother* 1985;35:267-80.
25. Eason CS, Hastings MJ, Deeley J, Bloxham B, Rivers RP, Marwood R. The effect of intrapartum chemoprophylaxis on the vertical transmission of group B streptococci. *Br J Obstet Gynaecol* 1983;90:633-5.

26. Matorras R, Garcia-Perea A, OmeZaca F, Diez-Enciso M, Madero R, Usandizaga JA. Intrapartum chemoprophylaxis of early-onset group B streptococcal disease. *Eur J Obstet Gynecol Reprod Biol* 1991;40:57–62.
27. Garland SM, Fliegner JR. Group B streptococcus (GBS) and neonatal infections: the case for intrapartum chemoprophylaxis. *Aust NZ J Obstet Gynaecol* 1991;31:119–22.
28. Yancey MK, Schuchat A, Brown LK, Ventura VL, Markenson GR. The accuracy of late antenatal screening cultures in predicting genital group B streptococcal colonization at delivery. *Obstet Gynecol* 1996;88:811–5.
29. Badri MS, Zawaneh S, Cruz AC, et al. Rectal colonization with group B streptococcus: relation to vaginal colonization of pregnant women. *J Infect Dis* 1977;135:308–12.
30. Mercer BM, Taylor MC, Fricke JL, Baselski VS, Sibai BM. The accuracy and patient preference for self-collected group B streptococcus cultures. *Am J Obstet Gynecol* 1995;173:1325–8.
31. CDC. Laboratory practices for prenatal group B streptococcal screening and reporting—Connecticut, Georgia, and Minnesota, 1997–1998. *MMWR* 1999;48:426–8.
32. Baker CJ, Edwards MS, Kasper DL. Role of antibody to native type III polysaccharide of group B streptococcus in infant infection. *Pediatrics* 1981;68:544–9.
33. Boyer KM, Gadzala CA, Burd LI, Fisher DE, Paton JB, Gotoff SP. Selective intrapartum chemoprophylaxis of neonatal group B streptococcal early-onset disease. I. Epidemiologic rationale. *J Infect Dis* 1983;148:795–801.
34. Schuchat A, Oxtoby M, Cochi S, et al. Population-based risk factors for neonatal group B streptococcal disease: results of a cohort study in metropolitan Atlanta. *J Infect Dis* 1990;162:672–7.
35. Schuchat A, Deaver-Robinson K, Plikaytis BD, Zangwill KM, Mohle-Boetani J, Wenger JD. Multistate case-control study of maternal risk factors for neonatal group B streptococcal disease. *Pediatr Infect Dis J* 1994;13:623–9.
36. Schuchat A, Zywicki S, Dinsmoor MJ, et al. Risk factors and opportunities for prevention of early-onset neonatal sepsis: a multicenter case-control study. *Pediatrics* 2000;105:21–6.
37. Zaleznik DF, Rench MA, Hillier S, et al. Invasive disease due to group B streptococcus in pregnant women and neonates from diverse population groups. *Clin Infect Dis* 2000;30:276–81.
38. Christensen KK, Dahlander K, Linden V, Svenningsen N, Christensen P. Obstetrical care in future pregnancies after fetal loss in group B streptococcal septicemia. A prevention program based on bacteriological and immunological follow-up. *Eur J Obstet Gynecol Reprod Biol* 1981;12:143–50.
39. Faxelius G, Bremme K, Kvist-Christensen K, Christensen P, Ringertz S. Neonatal septicemia due to group B streptococci—perinatal risk factors and outcome of subsequent pregnancies. *J Perinat Med* 1988;16:423–30.
40. Baker CJ, Edwards MS. Group B streptococcal infections. In: Remington J, Klein JO, eds. *Infectious diseases of the fetus and newborn infant*. Philadelphia: W.B. Saunders, 1990:742–811.
41. Schuchat A, Hilger T, Zell E, et al. Active Bacterial Core Surveillance of the Emerging Infections Program Network. *Emerg Infect Dis* 2001;7:92–9.
42. Jeffery HE, Lahra MM. Eight-year outcome of universal screening and intrapartum antibiotics for maternal group B streptococcal carriers. *Pediatrics* 1998;101(1). Available at <http://www.pediatrics.org/cgi/content/full/101/1/e2>.
43. Isaacs D, Royle JA, Australasian Study Group for Neonatal Infections. Intrapartum antibiotics and early onset neonatal sepsis caused by group B *Streptococcus* and by other organisms in Australia. *Pediatr Infect Dis J* 1999;18:524–8.
44. Davies HD, Adair CE, Schuchat A, Low DE, Sauve RS, McGeer A. Physicians' prevention practices and incidence of neonatal group B streptococcal disease in 2 Canadian regions. *CMAJ* 2001;164:479–85.
45. CDC. Adoption of perinatal group B streptococcal disease prevention recommendations by prenatal-care providers—Connecticut and Minnesota, 1998. *MMWR* 2000;49:228–32.
46. Watt JP, Schuchat A, Erickson K, Honig JE, Gibbs R, Schulkin J. Group B streptococcal disease prevention practices of obstetrician-gynecologists. *Obstet Gynecol* 2001;98:7–13.
47. Factor SH, Whitney CG, Zywicki S, Schuchat A, the Active Bacterial Core Surveillance Team. Effects of hospital policies based on 1996 group B streptococcal disease consensus guidelines. *Obstet Gynecol* 2000;95:377–82.
48. CDC. Hospital-based policies for prevention of perinatal group B streptococcal disease—United States, 1999. *MMWR* 2000;49:936–40.
49. Lieu TA, Mohle-Boetani JC, Ray GT, Ackerson LM, Walton DL. Neonatal group B streptococcal infection in a managed care population. *Obstet Gynecol* 1998;92:21–7.
50. Factor SH, Levine OS, Nassar A, et al. Impact of a risk-based prevention policy on neonatal group B streptococcal disease. *Am J Obstet Gynecol* 1998;179:1568–71.
51. Hafner E, Sterniste W, Rosen A, et al. Group B streptococci during pregnancy: a comparison of two screening and treatment protocols. *Am J Obstet Gynecol* 1998;179:677–81.
52. Riley L, Apollon M, Haider S, et al. “Real world” compliance with strategies to prevent early-onset GBS. Presented at the Infectious Diseases Society for Obstetrics and Gynecology Annual Scientific Meeting. Aug. 9–11, 2001, Quebec City, Canada.
53. Schuchat A, Roome A, Zell E, Linardos H, Zywicki S, O'Brien KL. Integrated monitoring of a new group B streptococcal disease prevention program and other perinatal infections. *Matern Child Health J* 2002;6:107–14.
54. Cheon-Lee E, Amstey MS. Compliance with the Centers for Disease Control and Prevention antenatal culture protocol for preventing group B streptococcal neonatal sepsis. *Am J Obstet Gynecol* 1998;179:77–9.
55. Katz VL, Moos M-K, Cefalo RC, Thorp JM, Bowes WA, Wells SD. Group B streptococci: results of a protocol of antepartum screening and intrapartum treatment. *Am J Obstet Gynecol* 1994;170:521–6.
56. Gilson GJ, Christensen F, Bekes K, Silva L, Qualls CR. Prevention of group B streptococcus early-onset neonatal sepsis: comparison of the Centers for Disease Control and Prevention screening-based protocol to a risk-based protocol in infants at greater than 37 weeks' gestation. *J Perinatol* 2000;20:491–5.
57. Brozanski BS, Jones JG, Krohn MA, Sweet RL. Effect of a screening-based prevention policy on prevalence of early-onset group B streptococcal sepsis. *Obstet Gynecol* 2000;95:496–501.
58. Davis RL, Hasselquist MB, Cardenas V, et al. Introduction of the new Centers for Disease Control and Prevention group B streptococcal prevention guideline at a large West Coast health maintenance organization. *Am J Obstet Gynecol* 2001;184:603–10.
59. Main EK, Slagle T. Prevention of early-onset invasive neonatal group B streptococcal disease in a private hospital setting: the superiority of culture-based protocols. *Am J Obstet Gynecol* 2000;182:1344–54.

60. Schrag SJ, Zell ER, Lynfield R, et al. A population-based comparison of strategies to prevent early-onset group B streptococcal disease in neonates. *N Engl J Med* 2002;347:233–9.
61. Rosenstein NE, Schuchat A. Opportunities for prevention of perinatal group B streptococcal disease: a multistate surveillance analysis. *Obstet Gynecol* 1997;90:901–6.
62. Rouse DJ, Goldenberg RL, Cliver SP, Cutter GR, Mennemeyer ST, Fargason CA, Jr. Strategies for the prevention of early-onset neonatal group B streptococcal sepsis: a decision analysis. *Obstet Gynecol* 1994;83:483–94.
63. Reisner DP, Haas MJ, Zingheim RW, Williams MA, Luthy D. Performance of a group B streptococcal prophylaxis protocol combining high-risk treatment and low-risk screening. *Am J Obstet Gynecol* 2000;182:1335–43.
64. Levine EM, Ghai V, Barton JJ, Strom CM. Intrapartum antibiotic prophylaxis increases the incidence of gram-negative neonatal sepsis. *Infect Dis Obstet Gynecol* 1999;7:210–13.
65. Lin FYC, Brenner RA, Johnson YR, et al. The effectiveness of risk-based intrapartum chemoprophylaxis for the prevention of early-onset neonatal group B streptococcal disease. *Am J Obstet Gynecol* 2001;184:1204–10.
66. Locksmith GJ, Clark P, Duff P. Maternal and neonatal infection rates with three different protocols for prevention of group B streptococcal disease. *Am J Obstet Gynecol* 1999;180:416–22.
67. CDC. Laboratory practices for prenatal group B streptococcal screening and reporting—Connecticut, Georgia and Minnesota, 1997–1998. *MMWR* 1999;48:426–8.
68. CDC. Adoption of hospital policies for prevention of perinatal group B streptococcal disease—United States, 1997. *MMWR* 1998;47:665–70.
69. Mohle-Boetani JC, Schuchat A, Plikaytis BD, Smith JD, Broome CV. Comparison of prevention strategies for neonatal Group B streptococcal infection: a population-based economic approach. *JAMA* 1993;270:1442–8.
70. Mohle-Boetani JC, Lieu TA, Ray GT, Escobar G. Preventing neonatal group B streptococcal disease: cost-effectiveness in a health maintenance organization and the impact of delayed hospital discharge for newborns who received intrapartum antibiotics. *Pediatrics* 1999;103:703–10.
71. Gotoff SP, Boyer KM. Prevention of early-onset neonatal group B streptococcal disease. *Pediatrics* 1997;99:866–9.
72. Benitz WE, Gould JB, Druzin ML. Antimicrobial prevention of early-onset group B streptococcal sepsis: estimates of risk reduction based on a critical literature review. *Pediatrics* 1999;103:e78. Available at <http://www.pediatrics.org/cgi/content/full/103/6/e78>.
73. Fargason CA, Peralta-Carcelen M, Rouse DJ, Cutter GR, Goldenberg RL. The pediatric costs of strategies for minimizing the risk of early-onset group B streptococcal disease. *Obstet Gynecol* 1997;90:347–52.
74. Schrag SJ, Arnold KE, Roome A, et al. Intrapartum antibiotic exposure in the era of perinatal group B streptococcal disease prevention [Abstract G-1824]. In: Program and abstracts of the 41st Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 2001.
75. Goodman LS, Gilman A, Gilman AG. Goodman and Gilman's The pharmacologic basis of therapeutics, Tenth edition. New York: Pergamon Press, 1990:1825.
76. Pylipow M, Gaddis M, Kinney JS. Selective intrapartum prophylaxis for group B streptococcus colonization: management and outcome of newborns. *Pediatrics* 1994;93:631–5.
77. Dunn AB, Blomquist J, Khouzami V. Anaphylaxis in labor secondary to prophylaxis against group B streptococcus: a case report. *J Reprod Med* 1999;44:381–4.
78. Aitmhand R, Moustauoui N, Belabbes H, Elmdaghri N, Benbachir M. Serotypes and antimicrobial susceptibility of group B streptococcus isolated from neonates in Casablanca. *Scand J Infect Dis* 2000;32:339–40.
79. Andrews JJ, Diekema DJ, Hunter SK, et al. Group B streptococci causing neonatal bloodstream infection: antimicrobial susceptibility and serotyping results from SENTRY centers in the Western Hemisphere. *Am J Obstet Gynecol* 2000;183:859–62.
80. Fernandez M, Hickman ME, Baker CJ. Antimicrobial susceptibilities of group B streptococci isolated between 1992 and 1996 from patients with bacteremia or meningitis. *Antimicrob Agents Chemother* 1998;42:1517–9.
81. Lin FYC, Azimi PH, Weisman LE, et al. Antibiotic susceptibility profiles for group B streptococci isolated from neonates, 1995–1998. *Clin Infect Dis* 2000;31:76–9.
82. Morales WJ, Dickey SS, Bornick P, Lim DV. Change in antibiotic resistance of group B streptococcus: impact on intrapartum management. *Am J Obstet Gynecol* 1999;181:310–4.
83. Silverman NS, Morgan M, Nichols WS. Antibiotic resistance patterns of group B streptococcus in antenatal genital cultures. *J Reprod Med* 2000;45:979–82.
84. Bland ML, Vermillion ST, Soper DE, Austin M. Antibiotic resistance patterns of group B streptococci in late third-trimester rectovaginal cultures. *Am J Obstet Gynecol* 2001;184:1125–6.
85. Berkowitz K, Regan JA, Greenberg E. Antibiotic resistance patterns of group B streptococci in pregnant women. *J Clin Microbiol* 1990;28:5–7.
86. Pearlman MD, Pierson CL, Faix RG. Frequent resistance of clinical group B streptococci isolates to clindamycin and erythromycin. *Obstet Gynecol* 1998;92:258–61.
87. Castor ML, Whitney C, Facklam R, et al. Antimicrobial susceptibility and serotype patterns of invasive group B *Streptococcus* isolates from Georgia, Minnesota, New York and Oregon, 1996–2000 [Abstract]. International Conference on Emerging Infectious Diseases 2002, program and abstract book. Atlanta: 2002, 132.
88. NCCLS. Performance Standard for Antimicrobial Susceptibility Testing, M100-S12. Table 2H. Wayne, PA, USA: NCCLS, 2002.
89. CDC. Sexually transmitted diseases treatment guidelines, 2002. *MMWR* 2002;51 (No. RR-6):28–9.
90. Kelkar PS, Li JT. Cephalosporin allergy. *N Engl J Med* 2001;345:804–9.
91. Lavin BS. Antibiotic cycling and marketing into the 21st century: a perspective from the pharmaceutical industry. *Infect Control Hosp Epidemiol* 2000;21:S32–5.
92. Baltimore RS, Huie SM, Meek JJ, Schuchat A, O'Brien KL. Early-onset neonatal sepsis in the era of group B streptococcal prevention. *Pediatrics* 2001;108:1094–8.
93. Cordero L, Sananes M, Ayers LW. Bloodstream infections in a neonatal intensive-care unit: 12 years' experience with an antibiotic control program. *Infect Control Hosp Epidemiol* 1999;20:242–6.
94. Joseph TA, Pyati SP, Jacobs N. Neonatal early-onset *Escherichia coli* disease: the effect of intrapartum ampicillin. *Arch Pediatr Adolesc Med* 1998;152:35–40.

95. Towers CV, Carr MH, Padilla G, Asrat T. Potential consequences of widespread antepartum use of ampicillin. *Am J Obstet Gynecol* 1998;179:879–83.
96. Gupta K, Scholes D, Stamm WE. Increasing prevalence of antimicrobial resistance among uropathogens causing acute uncomplicated cystitis in women. *JAMA* 1999;282:325–6.
97. Mercer BM, Carr TL, Beazley DD, Crouse DT, Sibai BM. Antibiotic use in pregnancy and drug-resistant infant sepsis. *Am J Obstet Gynecol* 1999;181:816–21.
98. Terrone DA, Rinehart BK, Einstein MH, Britt LB, Martin JN, Perry KG. Neonatal sepsis and death caused by resistant *Escherichia coli*: possible consequences of extended maternal ampicillin administration. *Am J Obstet Gynecol* 1999;180:1345–8.
99. Ramus RM, McIntire DD, Wendel GD, Jr. Antibiotic chemoprophylaxis for group B strep is not necessary with elective cesarean section at term [Abstract]. *Am J Obstet Gynecol* 1999;180:S85.
100. Hager WD, Schuchat A, Gibbs R, Sweet R, Mead P, Larsen JW. Prevention of perinatal group B streptococcal infection: current controversies. *Obstet Gynecol* 2000;96:141–5.
101. Kenyon SL, Taylor DJ, Tarnow-Mordi W, ORACLE Collaborative Group. Broad-spectrum antibiotics for preterm, prelabour rupture of fetal membranes: the ORACLE I randomised trial. *Lancet* 2001;357:979–88.
102. Kenyon SL, Taylor DJ, Tarnow-Mordi W, ORACLE Collaborative Group. Broad-spectrum antibiotics for spontaneous preterm labour: the ORACLE II randomised trial. *Lancet* 2001;357:989–94.
103. Gibbs RS, Jones PM, Wilder CJY. Internal fetal monitoring and maternal infection following cesarean section: a prospective study. *Obstet Gynecol* 1978;52:193–7.
104. Soper DE, Mayhall CG, Froggatt JW. Characterization and control of intraamniotic infection in an urban teaching hospital. *Am J Obstet Gynecol* 1996;175:304–10.
105. Seaward P, Gareth MB, Hannah ME, et al. International multicentre term prelabour rupture of membranes study: evaluation of predictors of clinical chorioamnionitis and postpartum fever in patients with prelabour rupture of membranes at term. *Am J Obstet Gynecol* 1997;177:1024–29.
106. Newton ER, Prihoda TJ, Gibbs RS. Logistic regression analysis of risk factors for intra-amniotic infection. *Obstet Gynecol* 1989;73:571–5.
107. Yancey MK, Duff P, Kubilis P, Clark P, Frentzen BH. Risk factors for neonatal sepsis. *Obstet Gynecol* 1996;87:188–94.
108. Hibbard JU, Shashoua A, Adamczyk C, Ismail M. Cervical ripening with prostaglandin gel and hygroscopic dilators. *Infect Dis Obstet Gynecol* 1998;6:18–24.
109. Boulvain M, Stan C, Irion O. Membrane sweeping for induction of labour (Cochrane Review). In: *The Cochrane Library*, Issue 4. Oxford: 2001.
110. Escobar GJ, Li D, Armstrong MA, et al. Neonatal sepsis workups in infants ≥ 2000 grams at birth: a population-based study. *Pediatrics* 2000;106:256–63.
111. Wiswell TE, Baumgart S, Gannon CM, Spitzer AR. No lumbar puncture in the evaluation for early neonatal sepsis: will meningitis be missed? *Pediatrics* 1995;95:803–6.
112. Visser VE, Hall RT. Lumbar puncture in the evaluation of suspected neonatal sepsis. *J Pediatr* 1980;96:1063–7.
113. Hristeva L, Booy R, Bowler I, Wilkinson AR. Prospective surveillance of neonatal meningitis. *Arch Dis Child* 1993;69:14–8.
114. Mitchell TF, Pearlman MD, Chapman RL, Bhatt-Mehta V, Faix RG. Maternal and transplacental pharmacokinetics of cefazolin. *Obstet Gynecol* 2001;98:1075–9.
115. Bromberger P, Lawrence JM, Braun D, Saunders B, Contreras R, Pettiti DB. The influence of intrapartum antibiotics on the clinical spectrum of early-onset group B streptococcal infection in term infants. *Pediatrics* 2000;106:244–50.
116. de Cueto M, Sanchez M-J, Sampedro A, Miranda J-A, Herruzo A-J, Rosa-Fraile M. Timing of intrapartum ampicillin and prevention of vertical transmission of group B streptococcus. *Obstet Gynecol* 1998;91:112–4.
117. Wiswell TE, Stoll BJ, Tuggle JM. Management of asymptomatic, term gestation neonates born to mothers treated with intrapartum antibiotics. *Pediatr Infect Dis J* 1990;9:826–31.
118. Mercer BM, Ramsey RD, Sibai BM. Prenatal screening for group B streptococcus. II. Impact of antepartum screening and prophylaxis on neonatal care. *Am J Obstet Gynecol* 1995;173:842–6.
119. Peralta-Carcelen M, Fargasan CA, Jr, Cliver SP, Cutter GR, Gigante J, Goldenberg RL. Impact of maternal group B streptococcal screening on pediatric management in full-term newborns. *Arch Pediatr Adolesc Med* 1996;150:802–8.
120. Balter S, Zell E, O'Brien K, et al. Evaluating the impact of intrapartum antibiotics to prevent group B streptococcus on the care and work-up of the neonate [Abstract]. In: *Program and Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy*. Washington DC: American Society for Microbiology, 2000:460.
121. Siegel JD, Cushion NB. Prevention of early-onset group B streptococcal disease: another look at single-dose penicillin at birth. *Obstet Gynecol* 1996;87:692–8.
122. Yancey MK, Armer T, Clark P, Duff P. Assessment of rapid identification tests for genital carriage of group B streptococci. *Obstet Gynecol* 1992;80:1038–47.
123. Walker CK, Crombleholme WR, Ohm-Smith MJ, Sweet RL. Comparison of rapid tests for detection of group B streptococcal colonization. *Am J Perinatol* 1992;9:304–8.
124. Bergeron MG, Ke D, Menard C, et al. Rapid detection of group B streptococci in pregnant women at delivery. *N Engl J Med* 2000;343:175–9.
125. Baker CJ, Rench MA, Edwards MS, Carpenter RJ, Hays BM, Kasper DL. Immunization of pregnant women with a polysaccharide vaccine of group B streptococcus. *N Engl J Med* 1988;319:1180–5.
126. Schuchat A, Wenger JD. Epidemiology of group B streptococcal disease: risk factors, prevention strategies and vaccine development. *Epidemiol Rev* 1994;16:374–402.
127. Baker CJ, Kasper DL. Correlation of maternal antibody deficiency with susceptibility to neonatal group B streptococcal infection. *N Engl J Med* 1976;294:753–6.
128. Baker CJ, Paoletti LC, Rench MA, et al. Use of capsular polysaccharide–tetanus toxoid conjugate vaccine for type II group B streptococcus in healthy women. *J Infect Dis* 2000;182:1129–38.
129. Baker CJ, Paoletti LC, Wessels MR, et al. Safety and immunogenicity of capsular polysaccharide–tetanus toxoid conjugate vaccines for group B streptococcal types Ia and Ib. *J Infect Dis* 1999;179:142–50.
130. Kasper DL, Paoletti LC, Wessels MR, et al. Immune response to type III group B streptococcal polysaccharide–tetanus toxoid conjugate vaccine. *J Clin Invest* 1996;98:2308–14.

131. Lin F-Y, Philips JB, III, Azimi PH, et al. Level of maternal antibody required to protect neonates against early-onset disease caused by group B *Streptococcus* type Ia: a multicenter, seroepidemiology study. *J Infect Dis* 2001;184:1022–8.
132. Davies HD, Adair C, McGeer A, et al. Antibodies to capsular polysaccharides of group B *Streptococcus* in pregnant Canadian women: relationship to colonization status and infection in the neonate. *J Infect Dis* 2001;184:285–91.
133. Schuchat A. Group B streptococcus. *Lancet* 1999;353:51–6.
134. Schuchat A. Epidemiology of group B streptococcal disease in the United States: shifting paradigms. *Clin Microbiol Rev* 1998;11:497–513.
135. Robbins JB, Schneerson R, Vann WF, Bryla DA, Fattom A. Prevention of systemic infections caused by group B streptococcus and *Staphylococcus aureus* by multivalent polysaccharide–protein conjugate vaccines. *Ann NY Acad Sci* 1995;754:68–82.
136. Rosa-Fraile M, Rodriguez-Granger J, Cueto-Lopez M, et al. Use of Granada medium to detect group B streptococcal colonization in pregnant women. *J Clin Microbiol* 1999;37:2674–7.
137. Gil EG, Rodriguez MC, Bartolome R, Berjano B, Cabero L, Andreu A. Evaluation of the Granada agar plate for detection of vaginal and rectal group B streptococci in pregnant women. *J Clin Microbiol* 1999;37:2648–51.
138. Votava M, Tejkalová M, Drábková M, Unzeitig V, Braveny I. Use of GBS media for rapid detection of group B streptococci in vaginal and rectal swabs from women in labor. *Eur J Clin Microbiol Infect Dis* 2001;20:120–2.
139. Stratton KR, Durch JS, Lawrence RS. *Vaccines for the 21st Century: A tool for decisionmaking*. Washington, DC: Institute of Medicine, National Academy Press, 1999.
140. Stoll BJ, Hansen N, Fanaroff AA, et al. Changes in pathogens causing early-onset sepsis in very-low-birth-weight infants. *N Engl J Med* 2002;347:240–7.
141. U. S. Department of Health and Human Services. *Healthy People 2010: understanding and improving health*. 2nd ed. Washington, DC: US Government Printing Office, 2000. Available at <http://www.health.gov/healthypeople>.
142. Schrag SJ, Whitney CG, Schuchat A. Neonatal group B streptococcal disease: how infection control teams can contribute to prevention efforts. *Infect Control Hosp Epidemiol* 2000;21:473–83.

Consultants

Kathryn Arnold, M.D., Georgia Division of Public Health, Atlanta, Georgia; Carol Baker, M.D., American Academy of Pediatrics/ Committee on Infectious Diseases, Elk Grove Village, Illinois; Gina Burns, M.S., Group B Strep Association, Chapel Hill, North Carolina; Richard Facklam, Ph.D., CDC, Atlanta, Georgia; Monica Farley, M.D., Infectious Diseases Society of America, Alexandria, Virginia; Theodore G. Ganiats, M.D., American Academy of Family Physicians, Leawood, Kansas; Ronald Gibbs, M.D., Infectious Diseases Society of Obstetricians and Gynecologists, Washington, D.C.; Paul Heath, M.D., U.K. GBS Prevention Working Group, London, England; James H. Jorgensen, Ph.D., Health Science Center at San Antonio, University of Texas, San Antonio, Texas; William Kanto, M.D., American Academy of Pediatrics/Committee on Fetus and Newborn, Elk Grove Village, Illinois; Shelene Keith, Jesse Cause Foundation—Saving the Babies from Group B Strep, Port Huenme, California; Tekoa King, M.P.H., American College of Nurse Midwives, Washington, D.C.; Feng Ying Lin, M.D., National Institute of Child Health and Development, National Institutes of Health, Bethesda, Maryland; Ruth Lynfield, M.D., Minnesota Department of Health, Minneapolis, Minnesota; Martin McCaffrey, M.D., Naval Medical Center, San Diego, California; Elliot Philipson, M.D., Cleveland Clinic, Cleveland, Ohio; Lisa Porter, M.Ed., Jacksonville, Florida; Laura Riley, M.D., American College of Obstetricians and Gynecologists, Washington, D.C.; Donna Russell, M.S., Washington Department of Health, Renton, Washington; Pam Sims, Pharm. D., Samford University, Birmingham, Alabama; Carol A. Spiegel, Ph.D., University of Wisconsin, Madison, Wisconsin; Barbara Stoll, M.D., Emory University School of Medicine, Atlanta, Georgia; Beth H. Stover, Healthcare Infection Control Practices Advisory Committee, CDC, Atlanta, Georgia; Cynthia Whitney, M.D., CDC, Atlanta, Georgia; Michael K. Yancey, M.D., Tripler Army Medical Center, Honolulu, Hawaii; Elizabeth Zell, M.Stat., CDC, Atlanta, Georgia

All *MMWR* references are available on the Internet at <http://www.cdc.gov/mmwr>. Use the search function to find specific articles.

Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of Health and Human Services.

References to non-CDC sites on the Internet are provided as a service to *MMWR* readers and do not constitute or imply endorsement of these organizations or their programs by CDC or the U.S. Department of Health and Human Services. CDC is not responsible for the content of these sites. URL addresses listed in *MMWR* were current as of the date of publication.

The *Morbidity and Mortality Weekly Report (MMWR)* series is prepared by the Centers for Disease Control and Prevention (CDC) and is available free of charge in electronic format and on a paid subscription basis for paper copy. To receive an electronic copy each week, send an e-mail message to listserv@listserv.cdc.gov. The body content should read *SUBscribe mmwr-toc*. Electronic copy also is available from CDC's Internet server at <http://www.cdc.gov/mmwr> or from CDC's file transfer protocol server at <ftp://ftp.cdc.gov/pub/publications/mmwr>. To subscribe for paper copy, contact Superintendent of Documents, U.S. Government Printing Office, Washington, DC 20402; telephone 202-512-1800.

Data in the weekly *MMWR* are provisional, based on weekly reports to CDC by state health departments. The reporting week concludes at close of business on Friday; compiled data on a national basis are officially released to the public on the following Friday. Address inquiries about the *MMWR* series, including material to be considered for publication, to Editor, *MMWR* Series, Mailstop C-08, CDC, 1600 Clifton Rd., N.E., Atlanta, GA 30333; telephone 888-232-3228.

All material in the *MMWR* series is in the public domain and may be used and reprinted without permission; however, citation of the source is appreciated.